# A novel, ataxic mouse model of Ataxia Telangiectasia caused by a clinically relevant nonsense mutation

3 Perez, Harvey <sup>¥1</sup>; Abdallah, May, F.<sup>¥1</sup>; Chavira, Jose, I. <sup>¥1</sup>; Egeland, Martin, T. <sup>1</sup>; Vo, Karen, L. <sup>1</sup>;

- 4 Buechsenschuetz, Callan, L.<sup>1</sup>; Sanghez, Valentina<sup>1</sup>; Kim, Jeannie, L.<sup>1</sup>; Pind, Molly<sup>2</sup>, Nakamura,
- 5 Kotoka <sup>3</sup>, Hicks, Geoffrey, G. <sup>2</sup>; Gatti, Richard, A. <sup>3</sup>; Madrenas, Joaquin <sup>1,5</sup>; Iacovino, Michelina <sup>1,4</sup>;

6 McKinnon, Peter, J.<sup>6</sup>; Mathews, Paul, J.<sup>\*1,7</sup>

- 1. The Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, CA
- Department of Biochemistry & Medical Genetics, Max Rady College of Medicine, University of
   Manitoba
- Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of
   California, Los Angeles, CA
- 12 4. Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA
- 13 5. Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA
- Center for Pediatric Neurological Disease Research, St. Jude Translational Neuroscience, St.
   Jude Children's Research Hospital, Memphis, TN, USA
- 16 7. Department of Neurology, Harbor-UCLA Medical Center, Torrance, CA
- 17 <sup>\*</sup>Contributed equally

18 \*Corresponding Author

## 19 Abstract

7

20 Ataxia Telangiectasia (A-T) is caused by null mutations in the genome stability gene, ATM (A-T mutated). 21 In mice, similar null mutations do not replicate A-T's characteristic severe ataxia with associated 22 cerebellar dysfunction and atrophy. By increasing genotoxic stress, through the insertion of null mutations 23 in the Atm (nonsense) and related Aptx (knockout) genes, we have generated a novel A-T mouse that 24 first develops mild ataxia, associated with abnormal Purkinje neuron (PN) activity and decreased size, 25 progressing to severe ataxia correlated with further reduced PN activity as well as PN loss and overall 26 cerebellar atrophy. These mice also exhibit high incidences of cancer and immune abnormalities that are 27 all hallmarks of the human disorder. Enabled by the insertion of a clinically relevant nonsense mutation 28 in Atm, we demonstrate that small molecule readthrough (SMRT) compounds can restore ATM 29 production, indicating their potential as a future A-T therapeutic.

## 30 1.0 Introduction

31 Ataxia Telangiectasia (A-T) is a rare (1 in ~100,000) (Swift et al. 1986), autosomal recessive genetic 32 disorder characterized by cancer predisposition, immune deficiency, and a progressive and severe ataxia 33 linked to cerebellar atrophy (Rothblum-Oviatt et al. 2016; Levy and Lang 2018; Boder and Sedgwick 34 1958). A-T patients typically die by their third decade of life (Crawford et al. 2006) from lymphatic cancers, 35 respiratory infections, or debilitating ataxia—unfortunately, survivability has not dramatically changed 36 since the 1950s (Micol et al. 2011; Rothblum-Oviatt et al. 2016). While disease progression and cause 37 of death vary widely across patients, the progressive decline in motor coordination is reported as having 38 the greatest negative impact on a patient's quality of life (Jackson et al. 2016). Care is generally palliative, 39 directed at reducing, limiting, or eliminating cancers or infections. No long-term therapies are available 40 for treating the ataxia and associated cerebellar atrophy.

41 A-T is caused by deficiency or dysfunction of the ATM (AT mutated) protein (Savitsky et al. 1995). 42 Premature termination codon (PTC) causing nonsense mutations account for over a third of known cases 43 with missense and deletions also contributing (Concannon and Gatti 1997; Sandoval et al. 1999). ATM 44 is a serine/threonine PIKK family kinase that is a key regulator of the DNA damage response (DDR), in 45 particular, responding to double stranded DNA breaks (Kastan and Bartek 2004; Shiloh and Ziv 2013). In the active monomeric form, ATM phosphorylates several key proteins halting the production of new 46 47 DNA (cell cycle arrest) (Ando et al. 2012), and then, depending on severity of the damage, initiating DNA 48 repair or programmed cell death (apoptosis) (Ando et al. 2012: Rashi-Elkeles et al. 2006). Several 49 downstream DDR pathway targets of ATM have been identified, including p53, CHK2, BRCA1, SMC1, 50 and NBS1 (Matsuoka et al. 2007). ATM's role in DNA repair is also implicated in normal immune system 51 development, where it is proposed to contribute to the recombination of natural DNA breaks that occur 52 during gene rearrangement in T- and B-lymphocyte maturation (Chao, Yang, and Xu 2000; Matei, 53 Guidos, and Danska 2006; Vacchio et al. 2007; Schubert, Reichenbach, and Zielen 2002). Although its 54 roles are still emerging, ATM has also been implicated in oxidative stress homeostasis (Guo et al. 2010) 55 and mitophagy (Valentin-Vega and Kastan 2012; Pizzamiglio, Focchi, and Antonucci 2020).

A mechanistic understanding of why ATM deficiency causes ataxia is still under debate, but it is far from the only DDR protein linked to ataxia, as aprataxin (APTX) (Aicardi et al. 1988), meiotic recombination 11 homolog 1 (MRE11) (Sedghi et al. 2018), nibrin (NBS1) (van der Burgt et al. 1996), senataxin (SETX) (Moreira et al. 2004), and tyrosyl-DNA phosphodiesterase 1 (TDP1) (Takashima et al. 2002) when absent or dysfunctional usually results in cerebellar related ataxia. This suggests that the neurological features of genome instability syndromes have a common underlying cause, although this idea is still to be clearly demonstrated (McKinnon 2009; Rass, Ahel, and West 2007).

63 Our understanding of why loss of DDR proteins like ATM selectively affect the cerebellum to cause ataxia 64 has been considerably hampered by the lack of animal models that recapitulate the neurological 65 symptoms (Lavin 2013). A number of A-T rodent models (Herzog et al. 1998; Xu and Baltimore 1996; 66 Elson et al. 1996; Barlow et al. 1996; Spring et al. 2001; Campbell et al. 2015; Quek et al. 2016; Tal et 67 al. 2018) as well as a porcine model (Beraldi et al. 2017) have been created by inserting gene mutations 68 that cause protein dysfunction (lack kinase activity) or complete deficiency. Unfortunately, none develop 69 an overt ataxic phenotype with marked cerebellar dysfunction and atrophy that recapitulates the human 70 disease. This has severely limited experimental studies from identifying the cellular and molecular 71 mechanisms by which DDR protein deficiency disrupts cerebellar function and atrophy.

72 We have created a novel mouse model that recapitulates the broadest set of A-T symptomology of any 73 A-T animal model to date, this includes for the first time a progressive and severe ataxia along with 74 cerebellar atrophy, a predisposition to cancer, and deficits in immune development. This model was 75 created by using a double-hit strategy, whereby the mouse is deficient not only in ATM, but also the DDR 76 protein APTX (aprataxin). As hypothesized, we found that deficiency in either ATM or APTX alone does 77 not lead to an overtly ataxic phenotype (Lavin 2013; Ahel et al. 2006), whereas deficiency in both DDR 78 genes resulted in mice that developed a progressive and profound ataxia. To improve the clinical 79 relevance of the Atm null mutation over prior A-T knockout mice, we inserted a clinically relevant point 80 mutation in the Atm gene (103C>T) that causes ATM deficiency due to the creation of a premature 81 termination codon (PTC). Moreover, the expression of the primary PTC allowed us to demonstrate that


a clinically related nonsense mutation in the A-T gene can be overcome by therapeutics capable of
enabling readthrough of PTCs. This includes the Small Molecule Readthrough (SMRT) compound we
have developed (Du et al. 2013).

## 85 2.0 Results

## 86 **2.1 Creation of a new AT mutant mouse model expressing a clinically relevant nonsense mutation**

87 To create a more clinically relevant mouse model of A-T we used a gateway recombination cloning and site-directed mutagenesis method to recapitulate a c.103C>T (p.R35X) mutation in the ATM gene found 88 89 in a large population of North African A-T patients (Fig. 1A and Methods) (Gilad et al. 1996). The 90 insertion of thymine in place of cytosine at this site in exon 3 results in a premature termination codon 91 (PTC) causing nonsense mutation in the ATM gene. Since the 103C>T mutation results in different PTCs 92 in the human compared to the mouse Atm gene, TGA vs. TAG respectively, we created two different 93 mice by exchanging the mouse Atm exon 3 with either a human or mouse exon 3 variant with the 103C>T 94 mutation (Fig. 1B). In the human version, a 103 CAG>TGA mutation of the mouse codon, where the 95 arginine (R) encoding codon becomes a TGA stop codon, results in a mouse we denote as AtmR35X. In 96 the mouse version, the 103C>T mutation transforms a glutamine (Q) encoding CAG codon into a TAG 97 stop codon and is denoted Atm<sup>Q35X</sup>. The presence of the PTC results in a loss of ATM expression, either 98 partially in the heterozygote, or completely in the homozygote (Fig. 1C).

99 Like prior ATM deficient A-T mouse models, neither the Atm<sup>R35X</sup> nor Atm<sup>Q35X</sup> mice develop a severe, 100 progressive ataxia, a hallmark characteristic of the human disease (Video S1). We therefore exploited a 101 double-hit strategy to increase genotoxic stress by eliminating expression of an additional DNA repair 102 pathway protein, specifically APTX, in order to overcome the apparent compensation for ATM deficiency 103 in mice. APTX deficiency alone in humans results in the disorder ataxia with ocular apraxia type 1 (AOA-104 1). In mice, ATM or APTX deficiency alone does not result in mice with an ataxic phenotype (Video S1 and S2). However, deficiency in both proteins, as in the AtmR35X/R35X; Aptx-/- mouse results in the 105 106 development of a severe and progressively ataxic phenotype (Video S3 and S4).



**Figure 1. New A-T mouse models expressing clinically related PTCs. A)** The *Atm* gene locus was targeted by homologous recombination of a targeting vector containing a modified NorCOMM cassette in intron one and the corresponding A-T PTC mutation in exon 3 to create the targeted  $Atm^{R35X}$  and  $Atm^{Q35X}$  ES cell lines. Following germline transmission of these alleles in mice, the floxed NorCOMM cassette was removed by Cre excision *in vivo* to produce the final  $Atm^{R35X}$  and  $Atm^{Q35X}$  mouse lines. **B)** Genotyping of AT mouse models. PCR agarose gel of mouse DNA shows 151 bp wt allele band and 241 bp Cre-excised targeted allele band. **C)** ATM immunoblot analyses from the indicated tissues in wildtype (Wt), heterozygous (het), and homozygous  $Atm^{R35x}$   $Atm^{Q35X}$  mice shows a gene dose effect of ATM protein expression. **D)** Breeding scheme schematic for double mutant and control mice for this study. **h** $\beta$ **A**: human beta Actin promotor.  $\Delta$ **TK1**: delta TK1, inactivated Thymidine Kinase 1. **T2A**: self-cleaving peptide sequence. **Neo**: Neomycin gene. **PGKpA**: Phosphoglycerate kinase poly A tail. **loxP** recombination elements are show as a blue triangle, orientation of the Gateway **attB** recombination elements by an orange arrow, orientation of the genotyping **F** and **R** primers is shown by green and blue arrows respectively, and engineered PTC sites are shown in exon 3 by a red stop sign.


108  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  mice were created by first crossing single mutant  $Atm^{R35X/R35X}$  (congenic on the 109 C57BL/6J background) and  $Aptx^{-/-}$  (mixed C57BL/6J and 129 background) mice to generate double 110 mutant heterozygote  $Atm^{R35X/Wt}$ ;  $Aptx^{-/+}$  mice. F1-5 littermate  $Atm^{R35X/Wt}$ ;  $Aptx^{-/+}$  mice were then crossed 111 within litters to create sufficient numbers of the desired experimental and control genotypes to understand 112 how loss of ATM and APTX affects the animal's phenotype (**Fig. 1D**). We found both male and female 113  $Atm^{R35X/R35X}$  and  $Atm^{Q35X/Q35X}$  mice to be reproductive, indicating functional reproductive systems.

#### 114 2.2 ATM deficient mice have lowered survivability and a high incidence of thymic cancer

115 We assessed the general health and development of control and experimental mice expressing different 116 levels of ATM and APTX (Fig. 2). We found that Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice grew ~55% slower and reached 117 estimated plateau weights that were  $\sim$ 35% less than control genotypes (log-rank, p<0.0001; Fig. 2A). 118 These differences in weight are a postnatal phenomenon, as no significant weight differences were 119 detected just after birth (P8) across all genotypes [1-way ANOVA, p>0.23]. Adolescent double mutant 120 mice at postnatal day 45 (P45) weighed on average 30% less in males [double mutant: 14.4±1.0 g vs. 121 wildtype: 20.2  $\pm$  0.5 g, t-test, p < 0.0001 and 25% less in females [double mutant: 12.7  $\pm$  0.6 g vs. wildtype: 17.0  $\pm$  0.2 g, t-test, p < 0.0001; Fig. 1A]. Differences across the control genotypes were 122 123 observed, but they were small and not consistent across time points or sex and therefore judged to not 124 be physiologically relevant (Fig. 2A).

125 Survivability of the Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice was significantly reduced compared to Atm<sup>Wt/Wt</sup>; Aptx<sup>+/+</sup> mice, 126 with 53% of mice still alive at 400 days of age, compared to 97% of Atm<sup>Wt/Wt</sup>; Aptx<sup>+/+</sup> mice at the same 127 time point (Fig. 2B). ATM deficiency alone was sufficient to reduce survivability, as compared to Atm<sup>WtWt</sup>; Aptx<sup>+/+</sup> mice, both Atm<sup>R35X/R35X</sup>; Aptx<sup>+/+</sup> and Atm<sup>R35X/R35X</sup>; Aptx<sup>-/+</sup> mice had significantly reduced survivability 128 129 rates [42%, log-rank,  $\chi^2_{(1, 56)}$  = 13.49, p=0.0002 and 52%, log-rank,  $\chi^2_{(1, 53)}$  = 19.54, p<0.0001, 130 respectively]. No significant difference between ATM deficient mice with partial or complete APTX 131 deficiency was detected [log-rank,  $\chi^2_{(2, 85)} = 1.01$ , p = 0.6]. Conversely, mice harboring at least one 132 functional copy of the Atm gene had survivability like Atm<sup>Wt/Wt</sup>; Aptx<sup>+/+</sup> mice, regardless of whether they 133 expressed APTX or not [log-rank,  $\chi^{2}_{(3, 131)}$  = 3.08, *p*=0.4]. No significant difference between male and

female mice was observed and thus data were pooled [log-rank, *p*>0.4 for all pairwise comparisons; **Fig. 2-fig. S1B**]. Generally, a third of mice with ATM deficiency died from complications related to large thymic
cancers found in the thoracic cavity (**Fig. 2C**). The presence or absence of APTX did not impact cancer
prevalence, and mice with at least one *Atm* transcript were cancer free up until at least P400. Overall,
ATM, but not APTX deficiency had severe effects on the health and survivability of the examined mice.




**Figure 2. Health and survivability of single and double mutant mice. A)** (left) The line color and symbol for each genotype is denoted and is consistent across all figures (1-7). (right)  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  mice weigh significantly less than the control genotypes as shown by the growth curves (solid line) along with the 95% confidence interval (dotted line). Growth curve ( $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  vs. controls): Male k = 0.024 vs. 0.011-0.019, Y<sub>max</sub> = 21.8 vs. 32.9-41.0 g, (n=3-18); Female k = 0.030 vs. 0.017-0.022, Y<sub>max</sub> = 16.9 vs. 23.3-31.3, (n=2-19). Sum of squares F-test run across all curves: Male  $F_{(12, 364)} = 30.5$ , \*\*\*\*p<0.0001, Female  $F_{(12, 339)} = 28.3$ , \*\*\*\*p<0.0001. **B**) ATM deficient mice, regardless of APTX expression displayed significantly lower survivability with ~55% of mice deceased by P400. Mice heterozygous for the R35X mutation ( $Atm^{R35X/W1}$ ;  $Aptx^{-/-}$ ) gene had similar survivability to wildtype ( $Atm^{WVW1}$ ;  $Aptx^{+/+}$ ) mice. Log-rank (Mantel-Cox) tests across all ( $\chi^2$  (6.217) = 48.4, \*\*\*\*p<0.0001) and single comparisons to wildtype (see figure) were conducted. Total number of animals indicated in panel **C**. **C**) ATM deficient mice displayed a high prevalence of thymic tumors based on postmortem necropsies. Other probable causes of death included enlarged livers, and obstructed kidneys. **Figure 2-figure supplement 1, Figure 2-Source Data 1** 

#### 139 **2.3 ATM** and APTX deficiency is necessary to produce progressive motor dysfunction

140 The progressive development of severe ataxia is a hallmark characteristic of A-T that is recapitulated in 141 the Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice but none of the other control genotypes we tested. Overall, we find motor 142 coordination deficits emerge between 210 and 400 days after birth in AtmR35X/R35X; Aptx-- mice and find 143 no evidence of ataxia in mice with at least some ATM or APTX expression (Fig. 3A, B). For the vertical 144 pole test, Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice took twice as long to descend at P400 compared to Atm<sup>Wt/Wt</sup>; Aptx<sup>+/+</sup>, Atm<sup>Wt/Wt</sup>; Aptx<sup>-/-</sup>, Atm<sup>R35X/R35X</sup>; Aptx<sup>+/+</sup>, or Atm<sup>Wt/R35X</sup>; Aptx<sup>-/-</sup> mice [Male: 29.1±0.9 (n=3) vs. 7.5±0.4 (n=12), 145 146  $12.5\pm 2.5$  (n=9),  $9.2\pm 0.9$  (n=10),  $8.6\pm 0.9$  (n=11) sec, 1-way ANOVA,  $F_{(4,40)} = 19.9$ , p<0.0001; Female: 147 19.0±4.0 (n=4) vs. 7.5±0.4 (n=12), 7.8±0.4 (n=10), 10.5±1.2 (n=6), 8.2±0.5 sec, 1-way ANOVA, F<sub>(4,35)</sub> = 13.9; p<0.0001]. An examination of gait indicated that Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice at P400, but not P210 148 149 need additional stabilization during ambulation, as they spend twice as much time with 3 paws, rather 150 than the normal 2 in contact with the ground as they walk across the gait analysis platform [Male: 56.2 151 vs. 26.4-32.2 %, 1-way ANOVA, F<sub>(4, 54)</sub> = 14.3, p<0.0001; Female: 58.4 vs. 18.9-28.8 %, 1-way ANOVA,  $F_{(3, 178)}$  = 95.5, *p*<0.0001; Fig. 3B]. Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> also display a slower cadence and average speed 152 153 across the platform compared to all other genotypes at P400 [cadence, Male: 9.5 vs. 13.3-15.9 steps/s, 154 1-way ANOVA, F<sub>(3, 204)</sub> = 36.8, p<0.0001; Female: 9.1 vs. 14.2-15.9 steps/s, 1-way ANOVA, F<sub>(3, 204)</sub> = 155 39.7, p<0.0001; speed, Male: 8.8 vs. 22-26 cm/s, 1-way ANOVA, F<sub>(4,50)</sub> = 28.3 p<0.0001; Female: 58.4 156 vs. 18.9-28.8 cm/s, 1-way ANOVA, F<sub>(3, 178)</sub> = 39.7, p<0.0001; Fig. 3B]. This difference in speed and 157 cadence is unlikely due to animal size, as there are no significant differences in these parameters at 158 earlier time points when the difference in size is nominal (Fig. 2A). These observations across the two 159 behavioral tests were found in both male and female mice at each of their respective time points, 160 consistent with the lack of sex differences observed in A-T patients.

We further examined behavioral differences between the  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  and  $Atm^{Wt/Wt}$ ;  $Aptx^{+/+}$  mice using a standardized set of experimental procedures used to phenotype genetically modified mice (i.e., SHIRPA; **Fig. 3C**; **Fig. 3-fig. S1**) (Rogers et al. 1997). We first detected differences in motor function at P8, where  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  mice took 3-4 times longer on average to right themselves compared to  $Atm^{Wt/Wt}$ ;  $Aptx^{+/+}$  mice [Male: 6.4±1.1 s (n=24) vs. 1.5±0.1 s (n=23), t-test, p<0.0002; Female: 11.1±1.9 s

166 (n=21) *vs.* 2.4±0.3 s (n=17), t-test, *p*<0.0002; **Fig. 3C bottom**]. At 30-days of age, we detected significant 167 differences between  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  and  $Atm^{WtWt}$ ;  $Aptx^{+/+}$  mice in behavioral tests that qualitatively 168 measure body position and spontaneous activity (**Fig. 3C**). Striking differences in  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$ 169 compared to  $Atm^{WtWt}$ ;  $Aptx^{+/+}$  mice were observed at P400, especially for behaviors related to movement,



**Figure 3.** *Atm*<sup>R35X/R35X</sup>; *Aptx<sup>-/-</sup>* mice develop a progressive loss in motor coordination. **A**) *Atm*<sup>R35X/R35X</sup>; *Aptx<sup>-/-</sup>* take a similar amount of time to descend a vertical pole at P45, 120, and 210, but significantly longer at P400. These overall results were found to be similar for both male (left, n=2-12) and female (right, n=4-12) mice. **B**) Consistent with the vertical pole test, the gait of *Atm*<sup>R35X/R35X</sup>; *Aptx<sup>-/-</sup>* mice measured during ambulation on a Catwalk gait analysis system was significantly different to controls by P400, but not before P210. This includes the percent of time a mouse spends with 3 vs. 1, 2, or 4 paws on the ground and the speed and cadence during each run across the platform. The effects of the two null mutations were generally similar between males (left, n=4-21) and females (right, n=3-18). **C**) *Atm*<sup>R35X/R35X</sup>; *Aptx<sup>-/-</sup>* (left) and *Atm*<sup>WUWI</sup>; *Aptx<sup>+/+</sup>* (right) at P30 and 400. Again, Male and Females performed similarly. A significant difference in the time to right during the righting reflex at P8 was observed in both Male and Female mice (bottom). **A** and **B** were examined via two-way ANOVA with age and genotype as factors followed by *potshot* Tukey's multiple comparison tests between *Atm*<sup>R35X/R35X</sup>; *Aptx<sup>-/-</sup>* and each of the control genotypes. Behavioral tests in **C** were examined using a non-parametric Kruskal Wallace followed by *postdocs* Dunn's multiple comparisons tests. Symbol/color key: *Atm*<sup>WUWI</sup>; *Aptx<sup>+/+</sup>* (purple circle), *Atm*<sup>WUWI</sup>; *Aptx<sup>+/-</sup>* (blue diamond), *Atm*<sup>R35X/R35X</sup>; *Aptx<sup>+/+</sup>* (green triangle), *Atm*<sup>R35X/R35X</sup>; *Aptx<sup>-/-</sup>* (orange square), *Atm*<sup>WUWI</sup>; *Aptx<sup>+/-</sup>* (red inverted triangle) **Figure 3-figure supplement 1, Figure 3-Source Data 1** 

including locomotor activity, body position, and gait (**Fig. 3C**). The results from this battery of tests demonstrates that  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  mice develop a severe change in behavior, especially in those related to motor function, by P400, consistent with purely visual observations of significant motor coordination deficits in the mice at this time point. Importantly, we do not find any significant differences between the other control genotypes, including  $Atm^{Wt/R35X}$ ;  $Aptx^{-/-}$  mice that express at least some ATM but no APTX protein (**Fig. 3-fig. S1**).


#### 176 2.4 ATM and APTX deficiency is necessary to disrupt cerebellar neural physiology

177 Ataxia in A-T is thought to result from cerebellar dysfunction; however, the progression and underlying 178 mechanism is unclear. Decreased spontaneous action potential firing rates in cerebellar Purkinje neurons (PN) has been linked to several forms of heritable ataxia (Cook, Fields, and Watt 2020). We therefore 179 sought to determine if PN action potential firing rates in Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> are abnormally low compared 180 181 to control mice. We extracellularly recorded action potentials from 3,300 PNs (Fig. 4A), across 188 182 animals, encompassing Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> and 3 other genotypes at 4 different time points (P45, 120, 183 210, and 400). Recordings were distributed across the lateral, intermediate and medial (vermis) 184 cerebellum of each mouse.

185 PN spontaneous firing frequency, averaged across all age groups was significantly lower in Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> compared to  $Atm^{WtWt}$ ;  $Aptx^{+/+}$  mice (**Fig. 4B**). The largest differences were detected in the anterior 186 187 [38.6±3.4 Hz (n=187) vs. 88.1±1.8 Hz (n=222)] and posterior [46.9±1.9 Hz (n=175) vs. 84.1±2.4 Hz 188 (n=219)] medial cerebellum [1-way ANOVA, p<0.0001; Fig. 4B]. Significant age dependent changes in 189 firing frequency were only observed in Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice, especially within the medial cerebellum 190 (Fig. 4C). The most significant decline occurring between P120 and 210 [anterior: 52.3±3.6 Hz (n=61)] 191 vs. 38.6±3.2 Hz (n=31), 1-way ANOVA, p=0.015; posterior: 48.4±3.1 Hz (n=63) vs. 34.8±3.2 Hz (n=25), 192 1-Way ANOVA, p=0.012. Moreover, we determined that age-dependent changes in PN activity in the 193 Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice were not equally expressed across the cerebellum, with the most pronounced 194 effects in lobules III, VI, VIII, and X (linear regression, p<0.05 for each folia; Fig. 4-figs. S1, S2). No 195 significant difference in PN firing frequency was detected between male and female mice within each 196 genotype, thus the data were pooled (2-way ANOVA, p>0.3 across all pairwise comparisons; Fig. 4-fig. 197 S3). Previous studies in mouse models of heritable ataxia indicate that physiological disruption in PN 198 firing not only includes changes in frequency but also affects its regularity (Cook, Fields, and Watt 2020). 199 We compared both the coefficient of variation (CV) and variability in adjacent intervals (CV2) between 200 AtmR35X/R35X; Aptx-- and control mice (Fig. 4-figs. S4, S5). No difference in these parameters across sex, 201 age, or genotype was detected. Consistent with the behavioral results, cerebellar dysfunction was found only in the Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice that developed ataxia and not in mice with at least some expression 202 203 of ATM or APTX.

#### 204 **2.5 ATM and APTX deficiency is necessary to induce cerebellar degeneration**

205 Cerebellar atrophy is a characteristic A-T feature that is absent in other A-T deficient mouse models. We 206 therefore assessed the developmental progression of cerebellar atrophy in the *Atm*<sup>R35X/R35X</sup>; *Aptx*<sup>-/-</sup> mice. 207 Structural changes in the overall size of the cerebellum were examined in *Atm*<sup>R35X/R35X</sup>; *Aptx*<sup>-/-</sup> and control 208 mice over 5 time points (P45, 120, 210, 400, 460; **Fig. 4D**). Cerebellar size was defined within each 209 animal by the ratio of 2-dimensional surface area of the dorsal cerebellum to the forebrain (i.e., 210 cerebellum area divided by forebrain area). The cerebellar size of control mice slightly increased during 211 adolescence and early adulthood (P45-P210), was generally stable through adulthood (P210-400), and



**Figure 4.** A reduction in PN firing rate, density, and size is associated with cerebellar atrophy in  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  mice. A) Schematic diagram of extracellular recording from a single Purkinje neuron (PN) in an acute cerebellar tissue slice preparation. Example electrophysiological traces for  $Atm^{WVWt}$ ;  $Aptx^{+/+}$  (purple, top) and  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  (orange, bottom) PNs in the medial (vermis) area of the cerebellum. **B**)  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  PN action potential firing frequencies were significantly slower compared to all control genotypes. Number of animals denoted at bottom of bar. Medial: ant. (lobules II-V), post. (lobules VI-IX) **C**) Action potential spiking frequency was compared across genotypes and for each anatomical subdivision. **D**) The size of the cerebellum decreased over age in  $Atm^{R35X/R35X}$ ;  $Aptx^{+/-}$  (n=5-10), but not control mice [ $Atm^{WVWt}$ ;  $Aptx^{+/+}$  (n=4-20),  $Atm^{WVWt}$ ;  $Aptx^{+/-}$  (n=4-12),  $Atm^{R35X/R35X}$ ;  $Aptx^{+/-}$  (n=6-16),  $Atm^{WVR35X}$ ;  $Aptx^{-/-}$  (n=6)]. 2-dimensional area estimates from dorsal images of the brain were used to determine forebrain and cerebellar area and the cerebellar to forebrain ratio is reported. **E**) Immunofluorescent images of  $Atm^{WVWt}$ ;  $Aptx^{+/+}$  (top) and  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  (bottom) at P45 and 400 (cerebellar lobule VIII). Scale bar = 100 um **F**) PN numbers (top) and soma diameter (bottom) in

*Atm<sup>WtWt</sup>; Aptx<sup>+/+</sup>* compared to *Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup>* mice at P45 (n=6) and 400 (n=5). Statistical significances were assessed via 2-way ANOVA with age and genotype as factors followed by *posthoc* Holm-Sidak pairwise multiple comparisons test in **B**, **C**, and **D**. T-tests were used in **F**. Symbol/color key: *Atm<sup>WtWt</sup>; Aptx<sup>+/+</sup>* (purple circle), *Atm<sup>WtWt</sup>; Aptx<sup>-/-</sup>* (blue diamond), *Atm<sup>R35X/R35X</sup>; Aptx<sup>+/+</sup>* (green triangle), *Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup>* (orange square), *Atm<sup>WtR35X</sup>; Aptx<sup>-/-</sup>* (red inverted triangle) **Figure 4-figure supplements 1-5, Figure 4-Source Data 1-3** 


213 then declined slightly in older age (P400-460). In stark contrast, relative cerebellar size in Atm<sup>R35X/R35X</sup>; 214 Aptx<sup>-/-</sup> mice progressively declined after P120. We however did not find cerebellar atrophy in mice with 215 some ATM expression [i.e.,  $Atm^{Wt/R35X}$ ;  $Aptx^{-/-}$ ; 1-way ANOVA,  $F_{(3.44)} = 1.2$ , p=0.32]. To rule out the possibility that reduced cerebellar size was related to the smaller stature of AtmR35X/R35X; Aptx-/- mice, we 216 217 examined, but did not find a correlation between animal weight and actual cerebellar size [Pearson's 218 correlation, p > 0.3 for all 4 genotypes at P460, n=10-20]. Furthermore, we found that cerebellar size did 219 not differ between male and the on average 22% smaller female mice across genotypes at this age [2-220 way ANOVA,  $F_{(2, 153)} = 1.9$ , p=0.2]. Therefore, cerebellar neurodegeneration in the Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> 221 mice, which begins after P120, is correlated with ATM and APTX deficiency.

222 In humans, cerebellar atrophy is associated with PN loss (Gatti and Vinters 1985). At the pathohistological 223 level, we found no difference in the linear density of Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> compared to Atm<sup>Wt/Wt</sup>; Aptx<sup>+/+</sup> 224 mice PNs at P45 [8.0  $\pm$  0.5 vs. 6.9  $\pm$  0.3 PNs/100 um, t-test, p=0.9], but did find PN diameter was significantly smaller [9.2 ± 0.3 vs. 10.2 ± 0.3 um, t-test, p=0.04; Fig. 4E, F]. At P400 however, the PN 225 226 density [4.3 ± 0.2 vs. 5.9 ± 0.3 PNs/100 um, t-test, p=0.003] and diameter [8.0 ± 0.4 vs. 9.9 ± 0.5 um, t-227 test, p=0.02] are reduced in Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> compared to Atm<sup>Wt/Wt</sup>; Aptx<sup>+/+</sup> mice (Fig. 4E, F). These 228 data indicate that subtle changes in cerebellar function correlate well with mild deficits in motor behavior, 229 but severe ataxia is associated with PN death and overall cerebellar atrophy.

#### 230 **2.6 Differential disruption of thymocyte development in ATM-deficient vs. APTX-deficient mice**

231 Chronic sinopulmonary infections associated with immunodeficiency are one of the leading causes of 232 death in A-T patients (Morrell, Cromartie, and Swift 1986; Bhatt and Bush 2014). Immunodeficiency is 233 linked to deficits in the generation of B- and T-lymphocytes that have been linked to defects in the antigen 234 receptor gene rearrangement processes during the generation of these cells in bone marrow and thymus, 235 respectively (Staples et al. 2008). The resulting defects in mature lymphocyte numbers include decreases in CD4<sup>+</sup> helper T-cells and killer CD8<sup>+</sup> T-cells (Schubert, Reichenbach, and Zielen 2002). We therefore
 examined the percentages of T-cells in peripheral blood and of different subpopulations in the thymus of
 Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice using T-cell antigen receptor (TCR) and CD4/CD8 co-receptor expression.

In the peripheral blood, we observed a significant reduction in the total fraction of CD3<sup>+</sup> T-cells in mice with reduced or absent ATM expression compared to wildtype mice (**Fig. 5**). This reduction was further compounded by concomitant deficiency of APTX. ATM and APTX deficiencies reduced T-cells in peripheral blood by over 65% decrease compared to wild type controls. The effect of APTX deficiency was additive to that of ATM deficiency suggesting a different mechanism of action for each of these two proteins on T-cell generation. The reduction in the percentage of T-cells in peripheral blood was mostly associated with reduction in the CD4+ helper T-cell population (**Fig. 5B**). Of interest, the proportion of




**Figure 5. T-cell deficits are found in the blood of** *Atm*<sup>R35X/R35X</sup>; *Aptx*<sup>-/-</sup> **mice. A)** Representative flow cytometric profiles of T-cell glycoprotein marker CD3 and summary plots indicate ATM and/or APTX deficient mice have decreased proportions of CD3<sup>+</sup> T-cells in the blood. **B)** Representative flow cytometric profiles of T-cell glycoprotein markers CD4 and CD8 gated on CD3<sup>+</sup> cells and summary plots for CD8 and CD4 single positive cell proportions. ATM deficient mice had reduced CD4<sup>+</sup> proportions compared to mice with at least one copy of the *Atm* gene. Statistical significances were assessed via 1-way ANOVA followed by *posthoc* Tukey's pairwise multiple comparisons tests. Number of animals denoted at bottom of bar. Symbol/color key: *Atm*<sup>Wt/Wt</sup>; *Aptx*<sup>+/+</sup> (purple circle), *Atm*<sup>Wt/Wt</sup>; *Aptx*<sup>-/-</sup> (blue diamond), *Atm*<sup>R35X/R35X</sup>; *Aptx*<sup>+/+</sup> (green triangle), *Atm*<sup>R35X/R35X</sup>; *Aptx*<sup>-/-</sup> (orange square), *Atm*<sup>Wt/R35X</sup>; *Aptx*<sup>-/-</sup> (red inverted triangle) **Figure 5/6-Source Data 1** 

CD8+ T-cells was increased only in Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice (Fig. 5B). Again, we observed a differential
effect of ATM and APTX deficiencies as seen for the effects of these mutations on the total T-cell fraction.

248 Given the reduction in T-cell populations in the blood, we next assessed T-cell development in the 249 thymus. In this organ, bone marrow-derived T-cell progenitors undergo TCR gene rearrangement 250 followed by positive selection for MHC restriction and negative selection of autoreactive clones. The 251 phases of thymocyte development can be followed by monitoring expression of CD4 and CD8 expression 252 in thymocytes. The progression of this developmental program goes from double negative (CD4<sup>-</sup>CD8<sup>-</sup>) 253 thymocytes, to double positive (CD4<sup>+</sup>CD8<sup>+</sup>) thymocytes and then to single positive (CD4<sup>+</sup> or CD8<sup>+</sup>) 254 thymocytes. In addition, within the double negative stage, four different subpopulations can be identified, 255 based on expression of CD25 and CD44, known as DN1 (CD44+CD25-), DN2 (CD44+CD25+), DN3 256 (CD25<sup>+</sup>CD44<sup>-</sup>) and DN4 (CD44<sup>-</sup>CD25<sup>-</sup>) (Germain 2002).

257 Gene rearrangement during thymocyte development occurs twice, once at the double negative thymocyte 258 stage in the CD25<sup>+</sup>CD44<sup>-</sup> stage (Krangel 2009) and then again in double positive thymocyte stage before 259 progressing into separate CD4<sup>+</sup> and CD8<sup>+</sup> single positive populations (Livák et al. 1999). ATM deficiency 260 has been linked to defects in both bouts of rearrangement in mice (Vachio 2007, Hathcock 2013). 261 Therefore, we compared the proportion of cells in the thymus expressing these different developmental cell surface markers in our ATM deficient and control mice (Fig. 6). Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> and Atm<sup>Wt/R35X</sup>; 262 263 Aptx<sup>-/-</sup>, but not Atm<sup>R35X/R35X</sup>; Aptx<sup>+/+</sup> mice had significantly elevated proportions of CD44<sup>+</sup>CD25<sup>-</sup>, 264 CD44<sup>+</sup>CD25<sup>+</sup>, and CD44<sup>-</sup>CD25<sup>+</sup> cells compared to wildtype (Fig. 6A). These increased proportions appear to be due in part to an impediment of CD44<sup>-</sup>CD25<sup>+</sup> cells maturing into CD44<sup>-</sup>CD25<sup>-</sup> double 265 negative cells, as the fraction of cells from Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> and Atm<sup>Wt/R35X</sup>; Aptx<sup>-/-</sup> mice is significantly 266 267 lower than wildtype (Fig. 6A). Of interest, APTX deficiency by itself had the greatest effect on the loss of 268 DN4 cells suggesting that APTX deficiency, rather than ATM deficiency, is responsible for this effect. To 269 our knowledge, this finding implicates for the first time APTX in gene rearrangement during the process 270 of TCR<sup>β</sup> recombination.

- 271 Next, we looked at the proportions of CD4<sup>+</sup>CD8<sup>+</sup> thymocytes compared to CD4<sup>+</sup>CD8<sup>-</sup> and CD4<sup>-</sup>CD8<sup>+</sup>
- single positive thymocytes in these four different strains. In agreement with our results in the blood and
- 273 prior studies, we found that ATM-deficient mice but not control mice displayed decreased expression of



#### Figure 6. ATM and APTX deficiency confer deficits in T-cell expression, but at different developmental

**stages. A)** Representative flow cytometric profiles of T-cell glycoprotein markers CD44 and CD25 gated on CD4<sup>-</sup>CD8<sup>-</sup> double negative (DN) cells. Summary plots show proportions of thymocytes at DN stages 1-4 (left to right). APTX deficient mice display increased proportions for DN1-3 and decreased proportion at DN4 consistent with a deficit in ontogeny from DN3 to DN4. **B)** Representative flow cytometric profiles of T-cell glycoprotein markers CD4 and CD8 gated. ATM deficient mice display decreased proportions for CD4 and CD8 single positive cells consistent with a deficit in ontogeny from CD4<sup>+</sup>CD8<sup>+</sup> double positive to CD4<sup>+</sup> and CD8<sup>+</sup> single positive fates. Statistical significances were assessed via 1-way ANOVA followed by *posthoc* Tukey's pairwise multiple comparisons tests. Number of animals denoted at bottom of bars. Symbol/color key: *Atm<sup>WVWM</sup>; Aptx<sup>+/+</sup>* (purple circle), *Atm<sup>WVWM;</sup> Aptx<sup>-/-</sup>* (blue diamond), *Atm<sup>R35X/R35X;</sup> Aptx<sup>+/+</sup>* (green triangle), *Atm<sup>R35X/R35X;</sup> Aptx<sup>-/-</sup>* (red inverted triangle) **Figure 5/6-Source Data 1** 

274  $CD4^+CD8^-$  and  $CD4^-CD8^+$  single positive thymocytes (**Fig. 6B**). These results support the role of ATM in 275 TCR  $\alpha/\delta$  gene rearrangement during thymocyte development (Bredemeyer et al. 2006), a role that is 276 independent of the role played by APTX in early thymocyte maturation.

#### 277 2.7 Readthrough molecules overcome PTC to restore ATM expression

278 By inserting a primary nonsense mutation to cause ATM deficiency, this new model is amenable to 279 efficacy testing of readthrough molecules with the potential to restore ATM expression by overcoming 280 the nonsense mutation causing PTC. As proof-of-principle that readthrough compounds can restore ATM 281 production, we exposed explant tissue harvested from ATM<sup>R35X</sup> and ATM<sup>Q35X</sup> mice with two different 282 readthrough compounds for 72 hrs, and then measured ATM expression to assess restoration. In both 283 types of ATM deficient mice, ATM expression was consistently restored in the spleen and cerebellum by 284 both G418, an aminogly coside previously known to have readthrough properties, and GJ103, a candidate 285 SMRT compound derivative created by our group (Fig. 7). These results demonstrate that ATM 286 expression can be restored by readthrough molecules in this mouse model, thereby creating the rationale 287 for in vivo efficacy testing of compounds with suitable pharmaco-dynamic and -kinetic properties in follow-288 on studies.




Figure 7. ATM protein expression is restored after readthrough compound exposure in explant tissues from AtmR35X/R35X and AtmQ35X/Q35X. Spleen and cerebellar explant tissue from Atm<sup>R35X/R35X</sup> and Atm<sup>Wt/Wt</sup> mice were treated readthrough with vehicle, the compounds G418 (100 µM) or GJ103 (100 µM) for 72 hrs. ATM immunoblots show recovery of ATM production in both the spleen (n=2) and cerebellum (n=3). Equal loading was assessed via housekeeping genes (Actin) and ponceau staining.

## 289 3.0 Discussion

290 By increasing genotoxic stress through the addition of a secondary hit to the DDR pathway, we generated 291 an A-T mouse that displays the most comprehensive set of A-T symptoms of any mouse model to date. 292 This includes a high incidence of cancer, defects in immune cell development, and most notably a severe 293 and progressive ataxia associated with cerebellar atrophy. Together, these comorbidities encompass the 294 three leading causes of premature death in A-T — each contributing to roughly a third. Of the 3 295 morbidities, the incapacitating effect of ataxia is the most penetrant; thus, it is reported by patients and 296 caregivers as having the greatest impact on guality of life. For this reason, the presence of ataxia and 297 cerebellar atrophy in this new mouse model is significant as it provides for the first time a resource to not 298 only investigate the mechanisms of neurological dysfunction but also, provides an important in vivo model 299 to test critically needed A-T therapeutics like the readthrough compounds tested here.

Our findings suggest two possibilities for why deficiency in genome stability proteins like A-T in mice do not result in comparably severe neurological deficits as it does in humans: **1**) rodents have redundancies in genome stability pathways in the brain thereby reducing the impact of ATM or APTX deficiency alone, or **2**) a mouse's lifespan is too short for genetic mutations that lead to genome instability to accumulate and cause dysfunction. The fact that the nervous system, compared to others, like the immune, requires

higher genotoxic pressure is an important question, and potentially points to differing mechanisms of
 action for ATM within different organ systems of the body.

307 In the immune system, ATM is implicated in the repair of DNA breaks that naturally occur during gene 308 rearrangement of antigen receptor genes in B- and T-cell precursors, a phenomenon critical for antigen 309 receptor (Ig and TCR) diversity of these cells. Our finding that T-cell proportions in the blood are 310 significantly reduced is consistent with prior studies in humans and A-T knockout mice (Schubert, 311 Reichenbach, and Zielen 2002; Hathcock et al. 2013; Chao, Yang, and Xu 2000; Barlow et al. 1996). 312 This reduction of T-cells in the periphery likely correlates with a defect in both cellular and humoral 313 immunity. Importantly, we found that expression of at least one copy of the ATM gene is enough to restore 314 CD4+ deficits in the blood indicating that therapies able to restore at least some ATM expression would 315 have therapeutic efficacy. Although we have not assessed B-cell development in this paper, it is likely 316 that similar conclusions would apply to that process given their mechanistic similarities.

317 As expected, the reduction on T-cells in peripheral blood correlated with defective thymocyte 318 development. In the thymus, we found two main defects. One, induced primarily by APTX deficiency, 319 manifests as a defect in the DN3 to DN4 transition coinciding with early rearrangement of TCR  $\beta$  locus. 320 The other defect, primarily caused by ATM deficiency, correlates with decreased progression of double 321 positive CD4<sup>+</sup>CD8<sup>+</sup> to single positive cells, primarily CD4<sup>+</sup> thymocytes. While the APTX finding was 322 surprising, as its deficiency (AOA 1) is not associated with immune deficits, APTX is known to interact 323 with TCR  $\beta$  gene rearrangement proteins, including XRCC4 (Clements et al. 2004). Future studies aimed 324 at defining APTX's role in end-joining mechanisms during TCR gene rearrangement will be important, 325 and the possibility that alternative end-joining mechanisms, like the use of microhomologies account for 326 the lack of an immune deficit in its absence need further investigation (Bogue et al. 1997).

In line with the 40% cancer prevalence found in A-T patients, we found roughly 30% of ATM deficient mice developed cancerous tumors. In humans, the most common cancers observed are leukemia (blood cell) and lymphoma (immune cell), with sporadic reports of ovarian, breast, and thyroid cancer. The tumors we observed in ATM deficient mice were almost exclusively thymic lymphomas that produced

large masses in the thoracic cavity. These tumors put pressure on the heart and lungs, leading to undersized organs that likely contributed to the animal's death. The thymic and lymphatic origins of these tumors raise the possibility that they arise from cell populations in the thymus that did not undergo proper gene rearrangement, a possibility that has received some consideration, but requires further exploration (Starczynski et al. 2003).

336 The survivability of Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice is considerably longer than prior A-T mouse models. In 337 comparison, the first A-T KO mouse model reported by Barlow et al. died from thymomas usually within 338 2-4 months after birth (Barlow et al. 1996). The increased severity of cancer survivability in this, and many 339 other knockout A-T mouse models is likely genetic, as the background strain harboring the mutation has 340 been shown to have significant effects on cancer prevalence and survivability, with A/J and C57BL/6 341 backgrounds having significantly increased survivability over the BALBC and 129S strains (Genik et al. 342 2014). The fact that our ATM deficient mice were created on a C57BL/6 background likely underlies their comparatively long lifespan. Given that the  $Atm^{R35X/R35X}$ ;  $Aptx^{+/+}$  mice do not develop ataxia, it is unlikely 343 344 that the early death in A-T KO mice prevents observation of an ataxic phenotype that would otherwise 345 develop in these mice. On the other hand, it is unknown whether the C57BL/6 background confers a 346 resilience to developing ataxia, as it does for cancer. Defining the genetic or possibly epigenetic factors 347 that influence the severity of the disease could provide avenues for future therapeutic development.

348 Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice developed a visually apparent and measurable progressive loss in motor 349 coordination. As is the case in A-T patients, the degree of ataxia observed in the A-T mice was not 350 uniform (Rothblum-Oviatt et al. 2016: Levv and Lang 2018: Boder and Sedgwick 1958). We found that 351 while all the Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice at P400 had visually apparent challenges moving around, there was 352 a significant variation in ataxia, from those that could still walk around, although clumsily in the cage, to 353 those moving almost solely by contortion. We observed motor differences in the AtmR35X/R35X; Aptx-/- mice 354 as early as 8 days old, where their time to right in the righting reflex was 5-10 times longer than control animals. Subtle differences in spontaneous activity and body position were qualitatively detected at P30, 355 356 however, the overall ability of Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice to ambulate was not dramatically affected until

after P210. By P400, multiple behavioral deficits were obvious, including changes in gait, increased startle reflex, tremor, and locomotor activity. One potential limitation of this model is the difference in temporal manifestation of ataxia, which develops at a developmentally later stage in the mice compared to humans. Additionally, the fact that this model expresses null mutations in two genome stability genes that has not been observed in human disease must be carefully factored into the interpretation of future experiments utilizing this new model.

363 Ataxia in A-T is linked to loss of cerebellar function due to its relatively selective neuropathology across 364 the brain and its known role in coordinated movement (Hoche et al. 2012). Consistent with patient 365 neuroimaging studies (Wallis et al. 2007; Sahama et al. 2015; Sahama et al. 2014; Dineen et al. 2020; 366 Tavani et al. 2003; Quarantelli et al. 2013), we find that cerebellar size in Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> mice is 367 initially normal, but eventually atrophies. Historically, correlations between the severity of atrophy and 368 ataxia in humans has not been straightforward, as postmortem assessment of cerebellar atrophy has not 369 necessarily been a good predictor of ataxia severity in human patients (Aguilar et al. 1968; Crawford et 370 al. 2006); although a recent neurometric and quantitative behavioral assessment study indicates a mild 371 correlation exists (Dineen et al. 2020). The central question underlying these findings is, to what extent 372 does cerebellar dysfunction, in the absence of, or prior to atrophy contribute to the ataxic phenotype vs. 373 atrophy itself. Since ataxia is often the first A-T symptom identified by parents and doctors, determining 374 whether future therapies will require replacing atrophied tissue or restore or halt changes in neuronal 375 function has significant ramifications.

Our observation that  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  mice display differences in cerebellar physiology, specifically decreased spontaneous PN action potential firing frequency, changes in morphology, and ultimately PN death is in line with multiple other ataxic mouse model studies, including those focused on spinocerebellar ataxias (SCA) 1, 2, 3, 5, 6, and 13 (see review (Cook, Fields, and Watt 2020)). In  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$ mice, we find that reduced PN firing frequency and morphological size is correlated with only mild behavioral deficits. As PN physiology progressively degrades the cerebellum atrophies resulting in severe ataxia. The underlying cause of the PN abnormality likely arises from changes in Ca<sup>+</sup> homeostasis as the

result of decreased Inositol 1,4,5-triphosphate receptor 1 (*Itpr1*) expression previously found in ATMdeficient mice (Kim et al. 2020), and is associated with changes in PN activity in SCA2. Moreover, we find that progressive decline in PN health is strongest in the vermis compared to the hemispheres. While the functional anatomy of the cerebellum is still under intense scrutiny, the medial cerebellum is considered to be an integral part of the spinocerebellum, receiving somatic sensory information from the spinal cord and motor cortex transforming information important for aspects of whole-body posture and locomotion (Machado et al. 2015; Apps and Garwicz 2005; Coffman, Dum, and Strick 2011).

390 Pinpointing where, when, and how ATM deficiency causes cerebellar pathology and ataxia has been a 391 challenge as prior ATM deficient mice generally lack the characteristic features needed to causally link 392 cellular and molecular deficits to the ataxic phenotype. Multiple promising avenues of investigation have 393 been defined, including those focused at the neuronal level where ATM is implicated in oxidative stress 394 signaling (Chen et al. 2003) and synaptic function (Li et al. 2009; Vail et al. 2016), as well as glial function, 395 where recent evidence suggests glial pathology may be a leading factor in cerebellar pathology 396 (Kaminsky et al. 2016; Campbell et al. 2016; Petersen, Rimkus, and Wassarman 2012; Weyemi et al. 397 2015). This novel animal model provides a new tool to test mechanistic hypotheses regarding how ATM 398 deficiency causes cerebellar pathology and ataxia as well as a testing platform for both previously 399 proposed therapeutic candidates (Browne et al. 2004; Chen et al. 2003) and our own SMRT compounds 400 (Du et al. 2013).

### 401 4.0 Materials and Methods

#### 402 4.1 Ethics Statement

This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All the animals were handled according to approved institutional animal care and use committee (IACUC) protocols at The Lundquist Institute (31374-03, 31773-02) and UCLA (ARC-2007-082, ARC-2013-068). The protocol was approved by the Committee on the Ethics of Animal Experiments of the Lundquist Institute (Assurance Number: D16-00213). Every effort was made to minimize pain and suffering by providing support when necessary and choosing ethical endpoints.

#### 409 **4.2 Mice**

All mice were group housed and kept under a 12 h day/night cycle with food and water available *ad libitum*. Animals were housed within the general mouse house population, and not in specialized pathogen free rooms. Older animals were made available wetted food or food gel packs on the ground of the cages as ataxia developed. *Atm*<sup>R35X</sup> and *Atm*<sup>Q35X</sup> mice were created and provided by Dr. Hicks and colleagues at the University of Manitoba.

These mice were created to contain the 103 C>T mutation found in a large population of North African AT patients, using recombineering Gateway technology and site-directed mutagenesis. A C>T mutation at this position in the mouse *Atm* gene creates a TAG G stop codon. The same mutation in the human ATM gene produces a TGA G stop codon. In consideration of the use of these models for therapeutic interventions, we chose to create a mouse model for each of the two PTC codons (**Fig. 1A**).

420 A modified Gateway R3-R4-destination vector was used to pull out the desired region of the mouse Atm 421 gene from a Bacterial Artificial Chromosome (BAC) and subsequently mutated to create either a TAG G 422 stop codon at codon 35 (M00001, position 103 (C>T)) or a TGA G stop codon (M00002, position 103 423 (CAG>TGA), replicating the human AT PTC). The genomic alleles were then cloned into a modified 424 version of the NorCOMM mammalian targeting vector using a 3-way Gateway Reaction (Bradley, 425 Anastassiadis et al. 2012). The resulting targeting vectors were electroporated into C2 ES cells 426 (C57BI/6N, derived in A. Nagy lab, Toronto, Canada, Gertsenstein, Nutter et al., 2010) and successfully 427 targeted clones were identified by selection with G418. Integration of the mutated targeting cassette into 428 the Atm gene locus was confirmed by Southern blot, and by sequencing of PCR products to confirm the 429 presence of the Atm PTC mutation, error free targeting into the Atm locus and error free functional 430 components of the vector (data not shown). Positive ES clones were used for blastocyst injection to 431 obtain the transgenic lines. The transgenic allele contained a floxed human beta actin promoter - delta 432 TK1- Neo cassette in the intron upstream of the region containing the mutated exon. This floxed cassette 433 was subsequently excised by crossing with a Cre driver mouse (B6.C-Tg(CMV-cre)1Cgn/J) to generate Atm<sup>R35X/Wt</sup> and Atm<sup>Q35X/Wt</sup> (MGI nomenclature: Atm<sup>TM1(103CAG>TGA)MFGC</sup> and Atm<sup>TM1(103C>T)MFGC</sup>, respectively) 434

mouse lines (Fig. 1A). Genotyping of the two *Atm* lines was performed by using the following primers at
Tm 62°C: Atm gene forward (F) primer: 5'-CCTTTGAGGCATAAGTTGCAACTTG-3'; and Atm gene
reverse (R) primer: 5'-GTACAGTGTATCAGGTTAGGCATGC-3', creating a Wild-type allele product of
151bp or targeted allele product of 241bp (Figs. 1A, 1B).

439 Atm<sup>R35X</sup> and Atm<sup>Q35X</sup> were backcrossed with C57BI/6J mice for 9 generations (99.2% isogenic) prior to 440 cryopreservation and subsequent rederivation using C57BI/6J surrogate mothers. Atm<sup>R35X</sup> and Atm<sup>Q35X</sup> 441 breeders were obtained from F1 sibling Atm<sup>R35X/Wt</sup> and Atm<sup>Q35X/Wt</sup> mice. Atm<sup>R35X/R35X</sup> and Atm<sup>Q35X/Q35X</sup> were 442 both found to be fertile. Aptx knockout (Aptx<sup>-/-</sup>) mice were created and provided to Dr. Mathews as 443 embryos from Dr. McKinnon (Ahel et al. 2006), and subsequently rederived via C57BI/6J surrogate 444 mothers. Aptx<sup>-/-</sup> mice are on a C57BI/6 and 129 mixed background. Atm<sup>R35X</sup>; Aptx<sup>KO</sup> mice of various Wt, heterozygous, and homozygous combinations were created from AtmR35X/Wt; Aptx-/+ breeders generated 445 446 by crossing AtmR35X/R35X and Aptx-/- mice. One cohort of double mutant and corresponding control mice 447 were used in the longitudinal behavioral study for gait analyses and SHIRPA testing (Figs. 2, 3). Multiple 448 additional cohorts of age matched double mutant and control mice were used for electrophysiological, 449 immunohistological, and Vertical Pole test experiments (Figs. 4, 7). Immunological and protein expression experiments were carried out using mice bred from the original Atm<sup>R35X</sup> and Atm<sup>Q35X</sup> rederived 450 451 mice (Figs. 5, 6, and 8).

Genotyping was performed from ear tissue samples of P8-11 mice. Real-time PCR methods conducted by Transnetyx Inc. were used to determine each animals' genotype. Animals were made identifiable via toe tattoos given at the same time as ear biopsy. Unique primers for *Atm<sup>R35X</sup>* and *Atm<sup>Q35X</sup>* were quantified and used to identify Wt, hetero- and homo-zygous mice (listed above). *Aptx<sup>-/-</sup>* and *Aptx<sup>Wt</sup>* primers were used to assess their genotypes.

#### 457 4.3 Animal Health

Animals were weighed via a digital scale at P8, 45, 120, 210, 400. Animal death was recorded as the day found dead, or on the day of euthanization when the animals reached a humane endpoint (animal unable to right itself within 60s, significant hair matting indicating lack of self-grooming, or excessive distress as noted

by the veterinary staff). Animal carcasses were immediately frozen upon death, and postmortem necropsies were carried out in batch. Probable cause of death was determined to the best of our ability in collaboration with the staff veterinarian (Dr. Catalina Guerra) by visual inspection of the internal organs. Some mice were cannibalized or accidentally disposed of by vivarium staff and were therefore labelled as "missing." Mice with no discernable visual cause of death were labelled "indeterminable." Mice that were found with thoracic masses near where the thymus would normally be in young mice were listed as "thymic cancer." All other identified probable causes of death (e.g., enlarged livers, urinary blockage) were labelled "other."

#### 468 **4.4 Behavior**

469 Before performing any behavioral test, mice were acclimated to the behavioral suite for ~20 minutes. Mice 470 were tested at varying times of the day, in line with their day cycle. A battery of behavioral tests was performed 471 on naïve double mutant mice of the indicated genotypes at various time points depending on the behavior but 472 in the same cohort of mice. The battery of tests included Catwalk Gait assessment (P45, 120, 210, 400) and 473 a subset of the SmithKline-Beecham Harwell Imperial-College and Royal-London-Hospital Phenotype 474 Assessment (SHIRPA) tests (P30 and 400). These tests were conducted by the UCLA Behavioral Core. 475 Double mutant and control mice were additionally examined on the Vertical Pole test. All behavioral apparatus 476 was wiped down with ethanol (70%) between each testing each subject.

#### 477 Gait Analysis

478 We used a Noldus Catwalk Gait analysis system designed to semi-automatically measure and analyze 479 the gait of mice during normal ambulation. Briefly, the movement of mice across a glass bottom corridor 480 is video recorded from a ventral position. Paw prints are highlighted in the video due to light illumination 481 across the glass walking platform. Each mouse step within a video is subsequently detected using Noldus software in a semi-automated fashion. A run for each mouse consists of 3 trials of consistent ambulation 482 483 across the monitored platform. Only consistent trials are accepted, and mice may take up to 10 attempts 484 to complete 3 compliant trials in either direction across the corridor. Compliant trials were defined as 485 those with movement across the platform under 5s long and with no more than 60% speed variation. 486 Once placed onto the platform, mice generally ran back and forth without any need for experimenter 487 prompting.

#### 488 Vertical Pole

Mice are placed at the top of an 80 cm tall bolt with their nose faced down and hind paws as close to the top as possible. Mice are immediately released, and time started immediately upon placement. Time is stopped when the first forepaw touches the surface below the pole. A mouse's natural predilection is to immediately climb down the pole, and they are given up to 60s to traverse the pole, otherwise they are helped off the pole. A non-completed trial is automatically given a time of 30s, as 95% of mice that did not descend within 30s were still on the pole at the 60s mark.

495 SHIRPA

Behavioral tests were conducted by the University of California, Los Angeles Behavioral Core at P30 and P400. All parameters are scored to provide a quantitative assessment, which enables comparison of results both over time and between different laboratories. Each mouse was sequentially tested across all behaviors within ~20 min. time span before moving onto the next mouse. The experimenter was blinded to animal genotype. The screen was performed as described previously (Rogers et al. 1997).

#### 501 <u>Behavioral Observation</u>

The primary screen provides a behavioral observation profile and assessment of each animal begins by observing undisturbed behavior in a viewing jar (10 cm diameter) for 5 min. In addition to the scored behaviors of **body position**, **spontaneous activity**, **respiration rate**, and **tremor**, the observer logs any instances of bizarre or stereotyped behavior and convulsions, compulsive licking, self-destructive biting, retropulsion (walking backwards) and indications of spatial disorientation.

#### 507 Arena Behavior

508 Thereafter, the mouse is transferred to the arena (30 cm x 50 cm) for testing of transfer arousal and 509 observation of normal behavior. The arena is marked into a grid of 10 cm<sup>2</sup> squares to measure locomotor 510 activity within a 30s period. While the mouse is active in the arena, measures of **startle response**, **gait**, 511 **pelvic elevation**, and **tail elevation** are recorded.

512 Supine Restraint

513 The animal is restrained in a supine position to record autonomic behaviors. During this assessment,

514 grip strength, body tone, pinna reflex, corneal reflex, toe pinch, wire maneuver, and heart rate, 515 were evaluated.

#### 516 Balance and Orientation

517 Finally, several measures of vestibular system function were performed. The righting reflex, contact

518 righting reflex, and negative geotaxis tests were performed. Throughout this procedure vocalization,

519 urination and general fear, irritability, or aggression were recorded.

#### 520 Equipment Used

521 1. Clear Plexiglas arena (approximate internal dimensions 55 x 33 x18 cm). On the floor of the arena

is a Plexiglas sheet marked with 15 squares (11 cm). A rigid horizontal wire (3 mm diameter) is

secured across the rear right corner such that the animals cannot touch the sides during the wire

524 maneuver. A grid (40 x 20 cm) with 12 mm mesh (approximate) is secured across the width of the

box for measuring tail suspension and grip strength behavior.

526 2. A clear Plexiglas cylinder (15 x 11 cm) was used as a viewing jar.

527 3. One grid floor (40 x 20 cm) with 12 mm meshes on which viewing jars stand.

528 4. Four cylindrical stainless-steel supports (3 cm high x 2.5 cm diameter) to raise grids off the bench.

529 5. One square (13 cm) stainless steel plate for transfer of animals to the arena.

530 6. Cut lengths of 3 / 0 Mersilk held in the forceps for corneal and pinna reflex tests

531 7. A plastic dowel rod sharpened to a pencil point to test salivation and biting.

8. A pair of dissecting equipment forceps, curved with fine points (125 mm forceps, Philip Harris
Scientific, Cat. No. D46-174), for the toe pinch.

534 9. A stopwatch.

535 10. An IHR Click box is used for testing the startle responses. The Click Box generates a brief 20 KHz
536 tone at 90dB SPL when held 30cm above the mouse. Contact Prof. K.P. Steel, MRC Institute of
537 Hearing Research, University Park, Nottingham NG7 2RD.

538 11. A ruler.

539 12. A 30 cm clear Plexiglas tube with an internal diameter of 2.5 cm for the contact righting reflex.

#### 540 4.5 Electrophysiology

#### 541 Preparation of acute cerebellar slices

Acute parasagittal slices of 300 um thickness were prepared from the cerebellum of experimental and control littermate mice by following published methods (Hansen et al., 2013). In brief, cerebella were quickly removed and immersed in an ice-cold extracellular solution with composition of (mM): 119 NaCl, 26 NaHCO<sub>3</sub>, 11 glucose, 2.5 KCl, 2.5 CaCl<sub>2</sub>, 1.3 MgCl<sub>2</sub> and 1 NaH<sub>2</sub>PO<sub>4</sub>, pH 7.4 when gassed with 5% CO<sub>2</sub>/95% O<sub>2</sub>. Cerebella were sectioned parasagittal using a vibratome (Leica VT-1000, Leica Biosystems, Nussloch, Germany) and initially incubated at 35°C for ~30 min, and then equilibrated and stored at room temperature until use.

#### 549 Extracellular Electrophysiology

550 Extracellular recordings were obtained from Purkinje neurons (PNs) in slices constantly perfused with 551 carbogen-bubbled extracellular solution (see above). Cells were visualized with DIC optics and a water-552 immersion 40× objective (NA 0.75) using a Zeiss Examiner microscope. Glass pipettes of  $\sim 3 M\Omega$ 553 resistance (Model P-1000, Sutter instruments, Novato, CA) were filled with extracellular solution and 554 positioned near PN axon hillocks in order to measure action potential-associated capacitive current 555 transients in voltage clamp mode with the pipette potential held at 0 mV. Data was acquired using a 556 MultiClamp 700B amplifier at 20 kHz, Digidata 1440 with pClamp10 (Molecular Devices, Sunnyvale, CA) 557 and filtered at 4 kHz. A total of 20 to 45 PNs were recorded from for each animal across all genotypes, 558 sexes, and age groups. Recordings were distributed across both the medial-lateral and rostro-caudal 559 axis of the cerebellum. Specifically, recordings were made from serial sections in the flocculus, lateral (2<sup>nd</sup> or 3<sup>rd</sup>), intermediate (6<sup>th</sup> or 7<sup>th</sup>), and medial (11<sup>th</sup> or 12<sup>th</sup>) slices. Lower number slices were used in the 560 561 younger age groups (P45 and 110) to roughly match the relative positioning of recordings across age 562 aroups, 0-3 recordings were made from each lobule within each slice dependent on tissue quality and 563 health. Each recording lasted for 1-minute. 3 to 5 mice were used for each age group and the 564 experimenter was blinded to the genotype, age, and sex.

#### 565 <u>Analyses</u>

566 Experiments were analyzed using standard and custom routines in Clampfit (Molecular Device), IgorPro 567 (Wavemetrics), and Excel (Microsoft). Specifically, action potentials were threshold detected and spiking 568 statistics (i.e., frequency and interval length), determined using adapted IgorPro routines (Taro Tools; 569 https://sites.google.com/site/tarotoolsregister/). The coefficient of variation of the mean interspike interval 570 (CV) and the median interspike interval (CV2=2 |ISIn+1-ISIn|/(ISIn+1+ISIn)) were calculated in Excel 571 using custom macros.

#### 572 **4.6 Examination of Cerebellar Degeneration**

#### 573 <u>Cerebellar size</u>

574 Immediately after brain removal from the skull, a dorsal, whole mount image was obtained. Images were 575 then processed using Fiji (NIH). The forebrain and cerebellar sizes were assessed by outlining their 2-576 dimensional space and then calculating area. We normalized for possible differences in overall brain size 577 by dividing the results of the cerebellum by forebrain size to produce a relative cerebellum to forebrain 578 ratio. Experimenters were blind to the genotype of the animal.

#### 579 Immunohistochemistry

580 At the respective study endpoints (P45, 120, 210, 400), male and female mice of all genotypes 581 represented in this study were anesthetized with isoflurane and underwent transcardial perfusion with 582 phosphate-buffered saline followed by 4% (w/v) buffered paraformaldehyde (PFA) and then dissected 583 to extract the brain. Images of the whole brain were taken immediately after removing the brain from 584 the skull and the brains were then submerged in 4% PFA for 24 hours, followed by 72 hours in 30% 585 sucrose in Tris-buffered saline (TBS) with 0.05% azide, and then cryoprotected in TBS-AF and stored 586 at 4°C until further use. The cerebellum was separated from the forebrain and parasagittally sectioned 587 using a sliding microtome (Microm HM 430, Thermo Scientific) set to section at 40µm thickness. 588 Cerebellum sections were collected in a series of six and stored in TBS-AF at 4° C until further use. For 589 immunofluorescent visualization of Purkinje neurons, cerebellum sections of both Atm<sup>Wt/Wt</sup>; Aptx<sup>+/+</sup> and  $Atm^{R35X/R35X}$ ; Aptx<sup>-/-</sup> (n=5 per genotype) were washed for 5 minutes in TBS three times, and then 590

591 blocked in 15% normal goat serum at room temperature for 30 minutes followed by free floating 592 incubation in rabbit anti-calbindin D-28k (1:1000, Swant cat# CB38a) for 1 hour at room temperature on 593 an orbital shaker, then washed for 5 minutes with TBS three times, followed by free floating incubation 594 in goat anti-rabbit Alexa Fluor 488 (1:1000, Invitrogen cat# A-11034) for 1 hour in the dark at room 595 temperature on an orbital shaker. Following secondary antibody incubation, sections were washed for 5 596 minutes in TBS three times and stored in TBS until further use. Sections were mounted and cover-597 slipped with Fluoromount-G with DAPI (Southern Biotech cat# 0100-20). Slides were scanned using 598 Stereo Investigator version 2020.1.3 64bit (MBF Bioscience) on a Zeiss Axio Imager.M2 microscope 599 (Carl Zeiss Microscopy) using a 20x objective (NA 0.5) and images captured with a Hamamatsu ORCA 600 Flash 4.0 LT C11440 digital camera (Hamamatsu Photonics). To guantify the number of calbindin-601 reactive cells in the resulting images, regions of interest were selected and drawn around the most 602 dorsal portion of the Purkinje neuron layer in lobule 8 of medial sections (based on the 603 electrophysiological differences previously observed) and the regions of interest were measured in 604 semi-automated fashion using a Smart Segmentation recipe (using Region: Area, Region: Percent 605 Area, and Region: Diameter, Mean as filters) on ImagePro Premier version 9.3 (Media Cybernetics). 606 Purkinje cell body size comparison was accomplished by using the mean diameter measurements 607 obtained in the previously described quantification of lobule VIII PNs. Cell quantification data was 608 visually inspected against the quantified images to ensure that only complete Purkinje cell bodies were 609 included in this analysis, any cells without full cell bodies apparent in the image were excluded.

610 Experimenter was blinded to mouse genotype.

#### 611 4.7 Flow Cytometry Measurements

Flow cytometry analysis of blood and thymus cells was performed by staining with specific anti-mouse antibodies: CD4 (Invitrogen cat# 50-0041-82) CD8 (Invitrogen cat# 53-0081-82) CD3 (Invitrogen cat#12-0031-83), CD44 (Invitrogen cat# 25-0441-82) and CD25 (Invitrogen cat# 47-0251-82). Briefly, wholeblood samples (50 ul) were stained using fluorescent-labeled antibodies, then red-blood cells were lysed using BD lysing solution (BD Biosciences cat# 349202) while live white-blood cells were stained using a

viability stain (BD Biosciences cat# 564996). Thymuses were mechanically dissociated. 1-2 million thymus cells were similarly stained using specific antibodies for CD4, CD8, CD44 and CD25. Analysis of immuno-stained white blood cells or thymus samples was performed using FACS ARIA III and data analyzed using FlowJo software as reported previously (Sanghez et al. 2017).

#### 621 4.8 Western Blots

622 Protein extracts (cells/tissues) were homogenized in radioimmunoprecipitation assay (RIPA) lysis buffer 623 (150 mM NaCl, 1% Nonidet P-40 [NP-40], 0.5% deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) with 624 protease inhibitors (10 ug/ml AEBSF, 10 ug/ml leupeptin, 5 ug/ml pepstatin, 5 ug/ml chymotrypsin, 10 625 ug/ml aprotinin) (Roche cat# 1167498001). The protein extracts were sonicated then pelleted by 626 centrifugation at 13,000 rpm for 15 min at 4°C. BCA protein assay (Pierce, 23250) was used to quantify 627 protein concentrations. Samples containing equal amounts of protein 50-100 up per lane were separated 628 using 4-12% gradient TGX precast gels BioRad (cat# 4561093EDU) then transferred by TransBlot Semi-629 Dry BioRad system (cat #1704150EDU) using Nitrocellulose transfer pack (cat# 1704158EDU). 630 Transferred blots were stained by Ponceau S stain for equal protein loading then washed and blocked 631 with 5% nonfat dry milk in TBST for 1hr at room temp. Primary antibodies were incubated with shaking 632 overnight at 4°C. Blots were probed for the following antibodies: ATM (D2E2) Rabbit mAb Cell Signaling, 633 (cat# 2873) at 1:1000 dilution, β-Actin (D6A8) Rabbit mAb Cell Signaling (cat#8457), GAPDH (D16H11) 634 Rabbit mAb Cell Signaling (cat #5174) followed by the appropriate horseradish peroxidase-conjugated 635 (HRP) secondary Anti-rabbit, Anti-mouse for 2 hours at room temperature. After multiple washes with 636 TBST, Protein expression was detected by Radiance Plus chemiluminescence substrate using the Azure 637 c400 and the BioRad ChemiDoc imaging systems. Densitometric analysis of the ATM was performed 638 using ImageJ. Experiments were performed with 2 technical and 2-3 biological replicates as indicated.

#### 639 4.9 Statistical Assessment

The number of animals chosen for each group was based on a priori power analyses using GPower v3.1
based on an α size of 0.5, power of 0.8, and effect sizes estimated from preliminary data or prior studies.
We used both parametric (1- and 2-way ANOVA) for normally distributed and non-parametric (Kruskal

- 643 Wallace) statistical methods for interval data to test for differences between groups followed by pairwise 644 multiple comparisons tests as indicated in the text. Outliers for immune data in Figs. 6 and 7 were 645 excluded via the ROUT method (Q=2%). The specific analyses used for each data set is noted in each 646 figure legend. For all figures: \*  $p \le 0.05$ , \*\* p < 0.01, \*\*\*\* p < 0.001, \*\*\*\* p < 0.0001. Data are represented as 647 mean ± SEM. All figures and statistical analyses were completed using Excel (Microsoft) or Prism v8 648 (Graphpad).
- 649 5.0 Acknowledgements
- 650 We would like to thank the UCLA Behavioral Core, especially Irina Zhuravka for her efforts assaying
- behavioral deficits in the mice.

## 652 6.0 Competing interests

653 The authors declare that no competing interests exist.

## 654 7.0 Citations

- Aguilar, Mary Jane, Shigehiko Kamoshita, Benjamin H. Landing, Elena Boder, and Robert P. Sedgwick. 1968.
   'Pathological Observations in Ataxia-Telangiectasia: A Report on Five Cases\*', *Journal of Neuropathology and Experimental Neurology*, 27: 659-76.
- Ahel, I., U. Rass, S. F. El-Khamisy, S. Katyal, P. M. Clements, P. J. McKinnon, K. W. Caldecott, and S. C. West. 2006.
  'The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates', *Nature*, 443: 713-6.
- Aicardi, J., C. Barbosa, E. Andermann, F. Andermann, R. Morcos, Q. Ghanem, Y. Fukuyama, Y. Awaya, and P. Moe.
   1988. 'Ataxia-ocular motor apraxia: a syndrome mimicking ataxia-telangiectasia', *Annals of Neurology*, 24:
   497-502.
- Ando, K., J. L. Kernan, P. H. Liu, T. Sanda, E. Logette, J. Tschopp, A. T. Look, J. Wang, L. Bouchier-Hayes, and S. Sidi.
   2012. 'PIDD death-domain phosphorylation by ATM controls prodeath versus prosurvival PIDDosome
   signaling', *Molecular Cell*, 47: 681-93.
- 667 Apps, Richard, and Martin Garwicz. 2005. 'Anatomical and physiological foundations of cerebellar information 668 processing', *Nature Reviews Neuroscience*, 6: 297-311.
- Barlow, C., S. Hirotsune, R. Paylor, M. Liyanage, M. Eckhaus, F. Collins, Y. Shiloh, J. N. Crawley, T. Ried, D. Tagle,
   and A. Wynshaw-Boris. 1996. 'Atm-deficient mice: a paradigm of ataxia telangiectasia', *Cell*, 86: 159-71.
- Beraldi, R., D. K. Meyerholz, A. Savinov, A. D. Kovacs, J. M. Weimer, J. A. Dykstra, R. D. Geraets, and D. A. Pearce.
  2017. 'Genetic ataxia telangiectasia porcine model phenocopies the multisystemic features of the human disease', *Biochim Biophys Acta Mol Basis Dis*, 1863: 2862-70.
- Bhatt, Jayesh M., and Andrew Bush. 2014. 'Microbiological surveillance in lung disease in ataxia telangiectasia',
   *European Respiratory Journal*, 43: 1797-801.

- 676 Boder, Elena, and Robert P. Sedgwick. 1958. 'ATAXIA-TELANGIECTASIA', A Familial Syndrome of Progressive 677 Cerebellar Ataxia, Oculocutaneous Telangiectasia and Frequent Pulmonary Infection, 21: 526-54.
- Bogue, M. A., C. Wang, C. Zhu, and D. B. Roth. 1997. 'V(D)J recombination in Ku86-deficient mice: distinct effects
  on coding, signal, and hybrid joint formation', *Immunity*, 7: 37-47.
- Bredemeyer, Andrea L, Girdhar G Sharma, Ching-Yu Huang, Beth A Helmink, Laura M Walker, Katrina C Khor, Beth
   Nuskey, Kathleen E Sullivan, Tej K Pandita, and Craig H Bassing. 2006. 'ATM stabilizes DNA double-strand break complexes during V (D) J recombination', *Nature*, 442: 466-70.
- Browne, Susan E., L. Jackson Roberts, Phyllis A. Dennery, Susan R. Doctrow, M. Flint Beal, Carrolee Barlow, and
   Rodney L. Levine. 2004. 'Treatment with a catalytic antioxidant corrects the neurobehavioral defect in
   ataxia–telangiectasia mice', *Free Radical Biology and Medicine*, 36: 938-42.
- Campbell, A., B. Krupp, J. Bushman, M. Noble, C. Pröschel, and M. Mayer-Pröschel. 2015. 'A novel mouse model
   for ataxia-telangiectasia with a N-terminal mutation displays a behavioral defect and a low incidence of
   Iymphoma but no increased oxidative burden', *Human Molecular Genetics*, 24: 6331-49.
- Campbell, Andrew, Jared Bushman, Joshua Munger, Mark Noble, Christoph Pröschel, and Margot Mayer-Pröschel.
   2016. 'Mutation of ataxia-telangiectasia mutated is associated with dysfunctional glutathione
   homeostasis in cerebellar astroglia', *Glia*, 64: 227-39.
- 692 Chao, Connie, Eva Marie Yang, and Yang Xu. 2000. 'Rescue of Defective T Cell Development and Function in
   693 Atm<sup>-/-</sup> Mice by a Functional TCRαβ Transgene', *The Journal of Immunology*, 164: 345-49.
- Chen, Philip, Cheng Peng, John Luff, Kevin Spring, Dianne Watters, Steven Bottle, Shigeki Furuya, and Martin F.
   Lavin. 2003. 'Oxidative Stress Is Responsible for Deficient Survival and Dendritogenesis in Purkinje
   Neurons from Ataxia-Telangiectasia Mutated Mutant Mice', *The Journal of Neuroscience*, 23: 11453-60.
- 697 Clements, P. M., C. Breslin, E. D. Deeks, P. J. Byrd, L. Ju, P. Bieganowski, C. Brenner, M. C. Moreira, A. M. Taylor,
  698 and K. W. Caldecott. 2004. 'The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM
  699 and interacts with the DNA strand break repair proteins XRCC1 and XRCC4', *DNA Repair (Amst)*, 3: 1493700 502.
- Coffman, Keith A., Richard P. Dum, and Peter L. Strick. 2011. 'Cerebellar vermis is a target of projections from the
   motor areas in the cerebral cortex', *Proceedings of the National Academy of Sciences*, 108: 16068-73.
- Concannon, P., and R. A. Gatti. 1997. 'Diversity of ATM gene mutations detected in patients with ataxia telangiectasia', *Human Mutation*, 10: 100-7.
- Cook, Anna A., Eviatar Fields, and Alanna J. Watt. 2020. 'Losing the Beat: Contribution of Purkinje Cell Firing
   Dysfunction to Disease, and Its Reversal', *Neuroscience*.
- Crawford, T. O., R. L. Skolasky, R. Fernandez, K. J. Rosquist, and H. M. Lederman. 2006. 'Survival probability in ataxia telangiectasia', *Archives of Disease in Childhood*, 91: 610-11.
- Dineen, Rob A., Felix Raschke, Hannah L. McGlashan, Stefan Pszczolkowski, Lorna Hack, Andrew D. Cooper, Manish
   Prasad, Gabriel Chow, William P. Whitehouse, and Dorothee P. Auer. 2020. 'Multiparametric cerebellar
   imaging and clinical phenotype in childhood ataxia telangiectasia', *NeuroImage: Clinical*, 25: 102110.
- Du, L., M. E. Jung, R. Damoiseaux, G. Completo, F. Fike, J. M. Ku, S. Nahas, C. Piao, H. Hu, and R. A. Gatti. 2013. 'A
   new series of small molecular weight compounds induce read through of all three types of nonsense
   mutations in the ATM gene', *Molecular Therapy*, 21: 1653-60.
- Elson, A., Y. Wang, C. J. Daugherty, C. C. Morton, F. Zhou, J. Campos-Torres, and P. Leder. 1996. 'Pleiotropic defects in ataxia-telangiectasia protein-deficient mice', *Proceedings of the National Academy of Sciences of the United States of America*, 93: 13084-9.
- Gatti, R. A., and H. V. Vinters. 1985. 'Cerebellar pathology in ataxia-telangiectasia: the significance of basket cells',
   *Kroc Foundation Series*, 19: 225-32.
- Genik, P. C., H. Bielefeldt-Ohmann, X. Liu, M. D. Story, L. Ding, J. M. Bush, C. M. Fallgren, and M. M. Weil. 2014.
  'Strain background determines lymphoma incidence in Atm knockout mice', *Neoplasia*, 16: 129-36.
- Germain, Ronald N. 2002. 'T-cell development and the CD4–CD8 lineage decision', *Nature Reviews Immunology*,
   2: 309-22.
- Gilad, Shlomit, Rami Khosravi, Dganit Shkedy, Tamar Uziel, Yael Ziv, Kinneret Savitsky, Galit Rotman, Sara Smith,
   Luciana Chessa, Timothy J. Jorgensen, Reli Harnik, Moshe Frydman, Ozden Sanal, Sima Portnoi, Zipora


- Goldwicz, N. G. J. Jaspers, Richard A. Gatti, Gilbert Lenoir, Martin F. Lavin, Kouichi Tatsumi, Rolf D. Wegner,
  Yosef Shiloh, and Anat Bar-Shira. 1996. 'Predominance of Null Mutations in Ataxia-Telangiectasia', *Human Molecular Genetics*, 5: 433-39.
- Guo, Zhi, Sergei Kozlov, Martin F. Lavin, Maria D. Person, and Tanya T. Paull. 2010. 'ATM Activation by Oxidative
   Stress', *Science*, 330: 517-21.
- Hathcock, K. S., S. Bowen, F. Livak, and R. J. Hodes. 2013. 'ATM influences the efficiency of TCRbeta rearrangement,
   subsequent TCRbeta-dependent T cell development, and generation of the pre-selection TCRbeta CDR3
   repertoire', *PloS One*, 8: e62188.
- Herzog, Karl-Heinz, Miriam J. Chong, Manuela Kapsetaki, James I. Morgan, and Peter J. McKinnon. 1998.
  'Requirement for Atm in Ionizing Radiation-Induced Cell Death in the Developing Central Nervous System', Science, 280: 1089-91.
- Hoche, F., K. Seidel, M. Theis, S. Vlaho, R. Schubert, S. Zielen, and M. Kieslich. 2012. 'Neurodegeneration in ataxia
   telangiectasia: what is new? What is evident?', *Neuropediatrics*, 43: 119-29.
- Jackson, Thomas J, Gabriel Chow, Mohnish Suri, Philip Byrd, Malcolm R Taylor, and William P Whitehouse. 2016.
   'Longitudinal analysis of the neurological features of ataxia-telangiectasia', *Developmental Medicine and Child Neurology*, 58: 690-97.
- Kaminsky, Natalie, Ofer Bihari, Sivan Kanner, and Ari Barzilai. 2016. 'Connecting Malfunctioning Glial Cells and
   Brain Degenerative Disorders', *Genomics, Proteomics & Bioinformatics*, 14: 155-65.
- Kastan, M. B., and J. Bartek. 2004. 'Cell-cycle checkpoints and cancer', *Nature*, 432: 316-23.
- Kim, Jusik, Keeeun Kim, Jung-Soon Mo, and Youngsoo Lee. 2020. 'Atm deficiency in the DNA polymerase β null
   cerebellum results in cerebellar ataxia and Itpr1 reduction associated with alteration of cytosine
   methylation', *Nucleic Acids Research*, 48: 3678-91.
- Krangel, Michael S. 2009. 'Mechanics of T cell receptor gene rearrangement', *Current Opinion in Immunology*, 21:
   133-39.
- Lavin, M. F. 2013. 'The appropriateness of the mouse model for ataxia-telangiectasia: neurological defects but no
   neurodegeneration', *DNA Repair (Amst)*, 12: 612-9.
- Levy, Ariel, and Anthony E. Lang. 2018. 'Ataxia-telangiectasia: A review of movement disorders, clinical features,
   and genotype correlations', *Movement Disorders*, 33: 1238-47.
- Li, J., Y. R. Han, M. R. Plummer, and K. Herrup. 2009. 'Cytoplasmic ATM in neurons modulates synaptic function',
   *Current Biology*, 19: 2091-6.
- Livák, Ferenc, Michelle Tourigny, David G. Schatz, and Howard T. Petrie. 1999. 'Characterization of TCR Gene
   Rearrangements During Adult Murine T Cell Development', *The Journal of Immunology*, 162: 2575-80.
- Machado, Ana S, Dana M Darmohray, Joao Fayad, Hugo G Marques, and Megan R Carey. 2015. 'A quantitative
   framework for whole-body coordination reveals specific deficits in freely walking ataxic mice', *Elife*, 4:
   e07892.
- Matei, I. R., C. J. Guidos, and J. S. Danska. 2006. 'ATM-dependent DNA damage surveillance in T-cell development
   and leukemogenesis: the DSB connection', *Immunological Reviews*, 209: 142-58.
- Matsuoka, Shuhei, Bryan A. Ballif, Agata Smogorzewska, E. Robert McDonald, Kristen E. Hurov, Ji Luo, Corey E.
   Bakalarski, Zhenming Zhao, Nicole Solimini, Yaniv Lerenthal, Yosef Shiloh, Steven P. Gygi, and Stephen J.
   Elledge. 2007. 'ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA
   Damage', *Science*, 316: 1160-66.
- 767 McKinnon, P. J. 2009. 'DNA repair deficiency and neurological disease', *Nature Reviews: Neuroscience*, 10: 100-12.
- Micol, R., L. Ben Slama, F. Suarez, L. Le Mignot, J. Beauté, N. Mahlaoui, C. Dubois d'Enghien, A. Laugé, J. Hall, J.
  Couturier, L. Vallée, B. Delobel, F. Rivier, K. Nguyen, T. Billette de Villemeur, J. L. Stephan, P. Bordigoni, Y.
  Bertrand, N. Aladjidi, J. M. Pedespan, C. Thomas, I. Pellier, M. Koenig, O. Hermine, C. Picard, D. Moshous,
  B. Neven, F. Lanternier, S. Blanche, M. Tardieu, M. Debré, A. Fischer, and D. Stoppa-Lyonnet. 2011.
  'Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype', *Journal of Allergy and Clinical Immunology*, 128: 382-9.e1.
- Moreira, M. C., S. Klur, M. Watanabe, A. H. Németh, I. Le Ber, J. C. Moniz, C. Tranchant, P. Aubourg, M. Tazir, L.
   Schöls, M. Pandolfo, J. B. Schulz, J. Pouget, P. Calvas, M. Shizuka-Ikeda, M. Shoji, M. Tanaka, L. Izatt, C. E.

- Shaw, A. M'Zahem, E. Dunne, P. Bomont, T. Benhassine, N. Bouslam, G. Stevanin, A. Brice, J. Guimarães,
  P. Mendonça, C. Barbot, P. Coutinho, J. Sequeiros, A. Dürr, J. M. Warter, and M. Koenig. 2004. 'Senataxin,
  the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2', *Nature Genetics*, 36: 225-7.
- Morrell, Daphne, Elizabeth Cromartie, and Michael Swift. 1986. 'Mortality and cancer incidence in 263 patients
   with ataxia-telangiectasia', *Journal of the National Cancer Institute*, 77: 89-92.
- Petersen, Andrew J., Stacey A. Rimkus, and David A. Wassarman. 2012. 'ATM kinase inhibition in glial cells activates
   the innate immune response and causes neurodegeneration in <em>Drosophila</em>', *Proceedings of the National Academy of Sciences*, 109: E656-E64.
- Pizzamiglio, L., E. Focchi, and F. Antonucci. 2020. 'ATM Protein Kinase: Old and New Implications in Neuronal
   Pathways and Brain Circuitry', *Cells*, 9.
- Quarantelli, Mario, Giuliana Giardino, Anna Prinster, Giuseppina Aloj, Barbara Carotenuto, Emilia Cirillo, Angela
   Marsili, Elena Salvatore, Ennio Del Giudice, and Claudio Pignata. 2013. 'Steroid treatment in Ataxia Telangiectasia induces alterations of functional magnetic resonance imaging during prono-supination
   task', *European Journal of Paediatric Neurology*, 17: 135-40.
- Quek, Hazel, John Luff, KaGeen Cheung, Sergei Kozlov, Magtouf Gatei, C. Soon Lee, Mark C. Bellingham, Peter G.
   Noakes, Yi Chieh Lim, Nigel L. Barnett, Steven Dingwall, Ernst Wolvetang, Tomoji Mashimo, Tara L.
   Roberts, and Martin F. Lavin. 2016. 'A rat model of ataxia-telangiectasia: evidence for a neurodegenerative
   phenotype', *Human Molecular Genetics*, 26: 109-23.
- Rashi-Elkeles, S., R. Elkon, N. Weizman, C. Linhart, N. Amariglio, G. Sternberg, G. Rechavi, A. Barzilai, R. Shamir,
   and Y. Shiloh. 2006. 'Parallel induction of ATM-dependent pro- and antiapoptotic signals in response to
   ionizing radiation in murine lymphoid tissue', *Oncogene*, 25: 1584-92.
- Rass, Ulrich, Ivan Ahel, and Stephen C. West. 2007. 'Defective DNA Repair and Neurodegenerative Disease', *Cell*,
   130: 991-1004.
- Rogers, D. C., E. M. Fisher, S. D. Brown, J. Peters, A. J. Hunter, and J. E. Martin. 1997. 'Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment', *Mammalian Genome*, 8: 711-3.
- Rothblum-Oviatt, Cynthia, Jennifer Wright, Maureen A. Lefton-Greif, Sharon A. McGrath-Morrow, Thomas O.
   Crawford, and Howard M. Lederman. 2016. 'Ataxia telangiectasia: a review', *Orphanet Journal of Rare Diseases*, 11: 159.
- Sahama, Ishani, Kate Sinclair, Simona Fiori, James Doecke, Kerstin Pannek, Lee Reid, Martin Lavin, and Stephen
   Rose. 2015. 'Motor pathway degeneration in young ataxia telangiectasia patients: A diffusion
   tractography study', *NeuroImage: Clinical*, 9: 206-15.
- Sahama, Ishani, Kate Sinclair, Kerstin Pannek, Martin Lavin, and Stephen Rose. 2014. 'Radiological imaging in ataxia
   telangiectasia: a review', *The Cerebellum*, 13: 521-30.
- Sandoval, N., M. Platzer, A. Rosenthal, T. Dork, R. Bendix, B. Skawran, M. Stuhrmann, R. D. Wegner, K. Sperling, S.
  Banin, Y. Shiloh, A. Baumer, U. Bernthaler, H. Sennefelder, M. Brohm, B. H. Weber, and D. Schindler. 1999.
  'Characterization of ATM gene mutations in 66 ataxia telangiectasia families', *Human Molecular Genetics*, 813
  8: 69-79.
- Sanghez, Valentina, Anna Luzzi, Don Clarke, Dustin Kee, Steven Beuder, Danielle Rux, Mitsujiro Osawa, Joaquín
   Madrenas, Tsui-Fen Chou, Michael Kyba, and Michelina Iacovino. 2017. 'Notch activation is required for
   downregulation of HoxA3-dependent endothelial cell phenotype during blood formation', *PloS One*, 12:
   e0186818.
- Savitsky, K., A. Bar-Shira, S. Gilad, G. Rotman, Y. Ziv, L. Vanagaite, D. A. Tagle, S. Smith, T. Uziel, S. Sfez, M.
  Ashkenazi, I. Pecker, M. Frydman, R. Harnik, S. R. Patanjali, A. Simmons, G. A. Clines, A. Sartiel, R. A. Gatti,
  L. Chessa, O. Sanal, M. F. Lavin, N. G. Jaspers, A. M. Taylor, C. F. Arlett, T. Miki, S. M. Weissman, M. Lovett,
- F. S. Collins, and Y. Shiloh. 1995. 'A single ataxia telangiectasia gene with a product similar to PI-3 kinase', *Science*, 268: 1749-53.

## Schubert, R., J. Reichenbach, and S. Zielen. 2002. 'Deficiencies in CD4+ and CD8+ T cell subsets in ataxia telangiectasia', *Clinical and Experimental Immunology*, 129: 125-32.

- Sedghi, Maryam, Mehri Salari, Ali-Reza Moslemi, Ariana Kariminejad, Mark Davis, Hayley Goullée, Björn Olsson,
   Nigel Laing, and Homa Tajsharghi. 2018. 'Ataxia-telangiectasia-like disorder in a family deficient for
   MRE11A, caused by a <em>MRE11</em> variant', *Neurology Genetics*, 4: e295.
- Shiloh, Yosef, and Yael Ziv. 2013. 'The ATM protein kinase: regulating the cellular response to genotoxic stress,
   and more', *Nature Reviews Molecular Cell Biology*, 14: 197-210.
- Spring, K., S. Cross, C. Li, D. Watters, L. Ben-Senior, P. Waring, F. Ahangari, S. L. Lu, P. Chen, I. Misko, C. Paterson,
  G. Kay, N. I. Smorodinsky, Y. Shiloh, and M. F. Lavin. 2001. 'Atm knock-in mice harboring an in-frame
  deletion corresponding to the human ATM 7636del9 common mutation exhibit a variant phenotype', *Cancer Research*, 61: 4561-8.
- Staples, E. R., E. M. McDermott, A. Reiman, P. J. Byrd, S. Ritchie, A. M. Taylor, and E. G. Davies. 2008.
  'Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene', *Clinical and Experimental Immunology*, 153: 214-20.
- Starczynski, Jane, William Simmons, Joanne R. Flavell, Phillip J. Byrd, Grant S. Stewart, Harjit S. Kullar, Alix Groom,
   John Crocker, Paul A. H. Moss, Gary M. Reynolds, Meri Glavina-Durdov, A. Malcolm R. Taylor, Christopher
   Fegan, Tatjana Stankovic, and Paul G. Murray. 2003. 'Variations in ATM protein expression during normal
   lymphoid differentiation and among B-cell-derived neoplasias', *The American journal of pathology*, 163:
   423-32.
- Swift, M., D. Morrell, E. Cromartie, A. R. Chamberlin, M. H. Skolnick, and D. T. Bishop. 1986. 'The incidence and gene frequency of ataxia-telangiectasia in the United States', *American Journal of Human Genetics*, 39: 573-83.
- Takashima, H., C. F. Boerkoel, J. John, G. M. Saifi, M. A. Salih, D. Armstrong, Y. Mao, F. A. Quiocho, B. B. Roa, M.
  Nakagawa, D. W. Stockton, and J. R. Lupski. 2002. 'Mutation of TDP1, encoding a topoisomerase Idependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy', *Nature Genetics*, 32: 267-72.
- Tal, Efrat, Marina Alfo, Shan Zha, Ari Barzilai, Chris I. De Zeeuw, Yael Ziv, and Yosef Shiloh. 2018. 'Inactive Atm
   abrogates DSB repair in mouse cerebellum more than does Atm loss, without causing a neurological
   phenotype', DNA Repair, 72: 10-17.
- Tavani, F., R. A. Zimmerman, G. T. Berry, K. Sullivan, R. Gatti, and P. Bingham. 2003. 'Ataxia-telangiectasia: the
   pattern of cerebellar atrophy on MRI', *Neuroradiology*, 45: 315-19.
- Vacchio, Melanie S., Alexandru Olaru, Ferenc Livak, and Richard J. Hodes. 2007. 'ATM deficiency impairs thymocyte
   maturation because of defective resolution of T cell receptor α locus coding end breaks', *Proceedings of the National Academy of Sciences*, 104: 6323-28.
- Vail, Graham, Aifang Cheng, Yu Ray Han, Teng Zhao, Shengwang Du, Michael M. T. Loy, Karl Herrup, and Mark R.
   Plummer. 2016. 'ATM protein is located on presynaptic vesicles and its deficit leads to failures in synaptic
   plasticity', Journal of Neurophysiology, 116: 201-09.
- Valentin-Vega, Y. A., and M. B. Kastan. 2012. 'A new role for ATM: regulating mitochondrial function and
   mitophagy', *Autophagy*, 8: 840-1.
- van der Burgt, I, K H Chrzanowska, D Smeets, and C Weemaes. 1996. 'Nijmegen breakage syndrome', *Journal of Medical Genetics*, 33: 153-56.
- 864 Wallis, LI, PD Griffiths, SJ Ritchie, CAJ Romanowski, G Darwent, and ID Wilkinson. 2007. 'Proton spectroscopy and 865 imaging at 3T in ataxia-telangiectasia', *American journal of neuroradiology*, 28: 79-83.
- Weyemi, Urbain, Christophe E. Redon, Towqir Aziz, Rohini Choudhuri, Daisuke Maeda, Palak R. Parekh, Michael Y.
   Bonner, Jack L. Arbiser, and William M. Bonner. 2015. 'NADPH oxidase 4 is a critical mediator in Ataxia
   telangiectasia disease', *Proceedings of the National Academy of Sciences*, 112: 2121-26.
- Xu, Y., and D. Baltimore. 1996. 'Dual roles of ATM in the cellular response to radiation and in cell growth control',
   *Genes and Development*, 10: 2401-10.

## 872 8.0 Figure Supplements



873

Figure 1-figure supplement 1. Animal weight for each time point and genotype. A) The average weights are plotted for each genotype at each of the indicated time points. Growth curves without experimental, 2-way ANOVA with age and genotype as factors. Male:  $F_{(10, 226)} = 5.6$ , p < 0.0001; Female:  $F_{(10, 197)} = 7.3$ , p < 0.0001 B) The survivability of each genotype of mice are plotted for male and female individually.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.






Figure 3-figure supplement 1. SHIRPA battery of behavioral tests. Behavioral deficits are seen only
 in *Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup>* mice across all behavioral tests and sexes. Behavioral tests were examined using
 a non-parametric Kruskal Wallace followed by *posthoc* Dunn's multiple comparisons tests.

884



885

**Figure 4-figure supplement 1. Heatmap showing significant PN firing frequency** *vs.* **age correlations in different lobules in** *Atm*<sup>*R*35X/*R*35X</sup>; *Aptx*<sup>-/-</sup> **and control mice.** Listed *p*-values indicate statistical differences from 0 based on linear regressions for the indicated lobules and areas. Red shaded boxes highlight *Atm*<sup>*R*35X/*R*35X</sup>; *Aptx*<sup>-/-</sup> folia with significantly decreasing PN firing frequency over age. Grey boxes indicate regions where PN firing frequency increased with age.



892

## 893 Figure 4-figure supplement 2. Mean variation between PN firing intervals across the cerebellum.

Average CV2 of PN firing frequency is plotted across the indicated locations at P45, 120, 210, and 400.






Figure 4-figure supplement 3. Mean PN firing frequency across genotype and sex. Average PN firing frequency for all cells recorded from male and female mice is plotted for the indicated genotype. No significant differences were observed between sex. 2-Way ANOVA with age and sex as factors,  $Atm^{WtWt}$ ;  $Aptx^{+/+}$  (F<sub>(1,751)</sub> = 1.15, p=0.3),  $Atm^{WtWt}$ ;  $Aptx^{-/-}$  (F<sub>(1,797)</sub> = 1.10, p=0.3),  $Atm^{R35X/R35X}$ ;  $Aptx^{+/+}$  (F<sub>(1,630)</sub> = 0.17, p=0.7),  $Atm^{R35X/R35X}$ ;  $Aptx^{-/-}$  (F<sub>(1,666)</sub> = 1.10, p=0.4), t-test for P400  $Atm^{Wt/R35X}$ ;  $Aptx^{-/-}$  (p=0.9)







Figure 4-figure supplement 4. Coefficient of Variation of PN firing frequency across the cerebellum. Average CV of PN firing frequency is plotted across the indicated locations at P45, 120, 210, and 400. No significant differences (p < 0.5) were detected across all areas using 2-way ANOVA with age and genotype as factors.



908 Figure 4-figure supplement 5. Mean variation between PN firing intervals across the cerebellum.

Average CV2 of PN firing frequency is plotted across the indicated locations at P45, 120, 210, and 400. No significant differences (p<0.5) were detected across all areas using 2-way ANOVA with age and genotype as factors.

## 912 9.0 Source files

- 913 Figure 2-Source Data 1. Weight, age of death, and probable cause of death
- 914 Figure 3-Source Data 1. Raw behavior data
- 915 Figure 4-Source Data 1. Individual average firing frequencies for each recorded cell
- 916 Figure 4-Source Data 2. Individual CV for each recorded cell
- Figure 4-Source Data 3. Brain area, Purkinje neuron density, and cell diameter for each animal
   and cell
- 919 Figure 5/6-Source Data 1. Tables of FACs data

## 920 10.0 Rich Media

- 921 Video S1. Pole test, Atm<sup>Wt/Wt</sup> vs. Atm<sup>R35X/R35X</sup>. Atm<sup>R35X/R35X</sup> do not display an ataxic phenotype at
  922 P460.
- 923 Video S2. Pole test, *Aptx<sup>+/+</sup> vs. Aptx<sup>-/-</sup>*. *Aptx<sup>-/-</sup>* mice do not display an ataxic phenotype at P460.
- 924 Video S3. Pole test, Atm<sup>Wt/Wt</sup>; Aptx<sup>+/+</sup> vs. Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup>. Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup> have considerable
  925 motor disability at P460.
- 926 Video S4. Open field, *Atm<sup>Wt/Wt</sup>; Aptx<sup>+/+</sup> vs. Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup>*. *Atm<sup>R35X/R35X</sup>; Aptx<sup>-/-</sup>* display a clear
  927 inability to ambulate in the open field at P460.







Fig. 2 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: h




bioRxiv preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint Figure is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint weight be the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.





bioRxiv preprint doi: https://doi.org/10.1101/2020.11.22.394098; this version posted November 23, 2020. The copyright holder for this preprint Figure is the second secon








Figure in the propriet doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint available under a CC-BY 4.0 International license.







Figure in the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: ht



bioRxiv preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint Figure is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint weise is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint weise is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint weise is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint weise is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint weise is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint weise is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint weise is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint weise is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint weise is the preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for the copyright holder for the copyright holder for th



bioRxiv preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint Figure and the preprint in perpetuity. It is made and



bioRxiv preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint Figure solution of the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.




Fig. bioRxiv preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint by bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.




Fig. bioRxiv preprint doi: https://doi.org/10.1101/2020.11.23.394098; this version posted November 23, 2020. The copyright holder for this preprint by bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

